ChromaDex (CDXC) 10-K19 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Jan. 03, 2015	Mar. 18, 2015	Jun. 28, 2014
Document And Entity Information
Entity Registrant Name	ChromaDex Corp.
Entity Central Index Key	1386570
Document Type	10-K
Document Period End Date	3-Jan-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-2
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$83,626,518
Entity Common Stock, Shares Outstanding		105,271,058
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jan. 03, 2015	Dec. 28, 2013
Current Assets
Cash	$3,964,750	$2,261,336
Trade receivables, less allowance for doubtful accounts and returns 2014 $38,000; 2013 $9,000	1,906,709	838,793
Other receivable		215,000
Inventories	3,734,341	2,204,125
Prepaid expenses and other assets	292,891	271,445
Total current assets	9,898,691	5,790,699
Leasehold Improvements and Equipment, net	1,264,660	1,063,239
Other Noncurrent Assets
Deposits and other	148,796	43,460
Long-term investment in affiliate		1,887,844
Intangible assets, net	296,061	201,650
Total other noncurrent assets	444,857	2,132,954
Total assets	11,608,208	8,986,892
Current Liabilities
Accounts payable	3,451,608	1,440,910
Accrued expenses	853,685	656,707
Current maturities of loan payable	223,358
Current maturities of capital lease obligations	148,278	138,887
Customer deposits and other	234,435	546,044
Deferred rent, current	69,456	55,586
Total current liabilities	4,980,820	2,838,134
Loan payable, less current maturities, net	2,068,474
Capital lease obligations, less current maturities	423,015	280,342
Deferred rent, less current	137,508	202,965
Total Liabilities	7,609,817	3,321,441
Stockholders' Equity
Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding 2014 105,271,058 and 2013 104,524,738 shares	105,271	104,525
Additional paid-in capital	43,417,442	39,697,063
Accumulated deficit	-39,524,332	-34,136,137
Total stockholders' equity	3,998,391	5,665,451
Total liabilities and stockholders' equity	$11,608,208	$8,986,892

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Statement of Financial Position [Abstract]
Allowance for doubtful accounts and returns	$38,000	$9,000
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	105,271,058	104,524,738
Common Stock, Shares, Outstanding	105,271,058	104,524,738

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Jan. 03, 2015	Dec. 28, 2013
Income Statement [Abstract]
Sales, net	$15,313,179	$10,160,964
Cost of sales	9,987,514	7,027,828
Gross profit	5,325,665	3,133,136
Operating expenses:
Sales and marketing	2,136,584	2,357,605
General and administrative	8,374,601	5,117,016
Loss from investment in affiliate	45,829	44,961
Operating expenses	10,557,014	7,519,582
Operating loss	-5,231,349	-4,386,446
Nonoperating income (expense):
Interest income	2,013	1,251
Interest expense	-158,849	-34,330
Nonoperating expenses	-156,836	-33,079
Net loss	($5,388,185)	($4,419,525)
Basic and Diluted loss per common share	($0.05)	($0.04)
Basic and Diluted weighted average common shares outstanding	106,459,379	99,987,443

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 29, 2012	$92,140	$33,617,801	($29,716,612)	$3,993,329
Beginning Balance, Shares at Dec. 29, 2012	92,140,062
Issuance of common stock, Shares	3,529,411
Issuance of common stock, net of offering costs, Amount	3,529	2,976,471		2,980,000
Exercise of stock options, Shares	276,038
Exercise of stock options, Amount	276	138,093		138,369
Exercise of warrants, Shares	7,979,227
Exercise of warrants, Amount	7,979	1,630,769		1,638,748
Share-based compensation, Shares	600,000
Share-based compensation, Amount	600	1,333,930		1,334,530
Net loss			-4,419,525	-4,419,525
Ending Balance, Amount at Dec. 28, 2013	104,525	39,697,063	-34,136,137	5,665,451
Ending Balance, Shares at Dec. 28, 2013	104,524,738
Issuance of common stock, net of offering costs, Amount
Issuance of warrant, Amount		246,189		246,189
Exercise of stock options, Shares	534,715
Exercise of stock options, Amount	535	466,614		467,149
Issuance of unvested restricted stock, Shares	1,186,000
Issuance of unvested restricted stock, Amount	1,186			1,186
Unvested restricted stock, Shares	-1,186,000			1,090,000
Unvested restricted stock, Amount	-1,186			-1,186
Share-based compensation, Shares	85,000
Share-based compensation, Amount	85	2,861,208		2,861,293
Stock issued to settle outstanding payable balance, Shares	126,605
Stock issued to settle outstanding payable balance, Amount	126	146,368		146,494
Net loss			-5,388,185	-5,388,185
Ending Balance, Amount at Jan. 03, 2015	$105,271	$43,417,442	($39,524,322)	$3,998,391
Ending Balance, Shares at Jan. 03, 2015	105,271,058

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Jan. 03, 2015	Dec. 28, 2013
Cash Flows From Operating Activities
Net loss	($5,388,185)	($4,419,525)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of leasehold improvements and equipment	222,721	246,175
Amortization of intangibles	35,589	23,532
Share-based compensation expense	2,916,924	1,287,917
Loss from disposal of equipment	20,400	66,378
Loss from investment in affiliate	45,829	44,961
Non-cash financing costs	49,527
Changes in operating assets and liabilities:
Trade receivables	-1,067,916	1,118,730
Other receivable	215,000	-215,000
Inventories	-1,530,216	-466,352
Prepaid expenses and other assets	-91,053	-62,913
Accounts payable	2,157,192	-1,618,450
Accrued expenses	196,978	-204,891
Customer deposits and other	-311,609	235,777
Deferred rent	-51,587	57,650
Net cash used in operating activities	-2,580,406	-3,906,011
Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment	-123,096	-137,349
Purchases of intangible assets	-130,000	-89,000
Proceeds from sale of assets		1,000,000
Proceeds from sale of equipment	1,356
Proceeds from investment in affiliate	1,842,015	225,000
Net cash provided by investing activities	1,590,275	998,651
Cash Flows From Financing Activities
Proceeds from issuance of common stock, net of issuance costs		2,980,000
Proceeds from exercise of stock options	467,149	138,369
Proceeds from exercise of warrants		1,638,748
Proceeds from loan payable	2,500,000
Payment of debt issuance costs	-102,866
Principal payments on capital leases	-170,738	-108,421
Net cash provided by financing activities	2,693,545	4,648,696
Net increase in cash	1,703,414	1,741,336
Cash Beginning of Year	2,261,336	520,000
Cash Ending of Year	3,964,750	2,261,336
Supplemental Disclosures of Cash Flow Information
Cash payments for interest	74,996	34,330
Supplemental Schedule of Noncash Investing Activity
Capital lease obligation incurred for the purchase of equipment	322,802	302,017
Retirement of fully depreciated equipment - cost	56,110
Retirement of fully depreciated equipment - accumulated depreciation	-56,110
Supplemental Schedule of Noncash Operating Activity
Stock issued to settle outstanding payable balance	146,494
Supplemental Schedule of Noncash Share-based Compensation
Stock awards issued for services rendered in prior period		14,560
Changes in prepaid expenses associated with share-based compensation	55,631	32,053
Warrant issued, net of offering costs	246,189
Supplemental Schedule of Noncash Activities Related to Sale of BlueScience Consumer Product Line
Assets transferred		3,526,677
Liabilities transferred		368,873
Carrying value of long-term investment in affiliate, net of $1,000,000 cash proceeds		$2,157,804

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
Statement of Cash Flows [Abstract]
Cash proceeds		$1,000,000

Nature_of_Business_and_Liquidi

Nature of Business and Liquidity	12 Months Ended
Nature of Business and Liquidity	Jan. 03, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Liquidity	Nature of business: ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., Chromadex Analytics, Inc. and Spherix Consulting, Inc. (collectively, the “Company”) are a natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, catalog of natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting services. The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The Company acquired Spherix Consulting, Inc. on December 3, 2012, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks. In 2011, the Company launched its BluScience retail consumer line based on its proprietary ingredients. However, on March 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci International Inc. and consummated the sale of BluScience consumer product line to NeutriSci.

	Liquidity: The Company has incurred a loss from operations of approximately $5.2 million and a net loss of approximately $5.4 million for the year ended January 3, 2015, and a net loss of approximately $4.4 million for the year ended December 28, 2013. As of January 3, 2015, the cash and cash equivalents totaled approximately $3,965,000.

	On September 29, 2014, we entered into a loan and security agreement (the “Loan Agreement”) with Hercules Technology II, L.P., as lender (“Lender”) and Hercules Technology Growth Capital, Inc., as agent. Lender will provide us with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at closing, and is repayable in installments over 30 months, following an initial interest-only period of twelve months after closing. The remaining $2.5 million of the term loan can be drawn down at our option at any time but no later than July 31, 2015. The term loan bears interest at the rate per year equal to the greater of either (i) 9.35% plus the prime rate as reported in The Wall Street Journal minus 3.25%, or (ii) 9.35%. For further details on the Loan Agreement, please refer to Note 8. Loan Payable.

	While we anticipate that our current cash, cash equivalents and cash generated from operations and $2.5 million we can additionally draw down at our option pursuant to the Loan Agreement will be sufficient to meet our projected operating plans through at least March 20, 2016, we may require additional funds, either through additional equity or debt financings or collaborative agreements or from other sources. We have no commitments to obtain such additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

Significant_Accounting_Policie

Significant Accounting Policies

12 Months Ended

Jan. 03, 2015

Accounting Policies [Abstract]

Significant Accounting Policies

Significant accounting policies are as follows:

Basis of presentation: The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on the Saturday closest to December 31. The fiscal year ended January 3, 2015 (referred to as 2014) consisted of 53 weeks and the fiscal year ended December 28, 2013 (referred to as 2013) consisted of 52 weeks. Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date. The fiscal year 2015 will include 52 weeks.

Use of accounting estimates: The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Changes in accounting estimates: During the year ended January 3, 2015, the Company evaluated assumptions for estimating the fair value of the Company’s stock options. The Company uses the Black-Scholes based option valuation model, which requires assumptions on (i) volatility, (ii) expected dividends, (iii) expected term and (iv) risk-free rate. While evaluating the assumptions on volatility, the Company determined that the historical volatility the Company’s common stock needs to be considered when estimating the expected volatility. Previously, the Company calculated expected volatility based principally on the volatility rates of similarly situated publicly held companies, as the historical measurement period that was available to compute the volatility rate of the Company’s common stock was shorter than the expected life of the options.

For stock options granted during the year ended January 3, 2015, the Company calculated expected volatility rate based on the combined volatility of publicly held companies in similar industries and volatility of the Company’s common stock. Based on the expected term of stock options, a 20~75% weight was assigned to the volatility of the Company’s common stock as the historical volatility of the Company’s common stock from June 2008 through April 2010 was exceptionally high due to a thinly traded market. Below table illustrates the Company’s historical volatility and the average daily trading volume of the Company’s common stock from June 2008 through April 2010 and from April 2010 through December 2014.

Period

Volatility

Average Daily

Trading Volume

6/20/2008 ~ 4/19/2010

402

11,455

4/20/2010 ~ 1/2/2015

155,111

The weighted average expected volatility for the stock options granted during the twelve-month period ended January 3, 2015 following the update to our estimate is approximately 75%. The weighted average expected volatility would have been approximately 30%, had we computed solely based on the volatility rates of similarly situated public companies. For the year ended December 28, 2013, the weighted average expected volatility the Company used to estimate the fair value of the Company’s stock options granted was approximately 33%.

The following is a pro-forma disclosure of our historical calculation of estimated volatility over the expected term based on a grant with an expected term of 6 years:

Fiscal Year 2013

Name

Use

Volatility

Name

Use

Volatility

Covance, Inc.

ChromaDex Corp.

243

Sigma-Aldrich Corp.

Covance Inc.

Sigma-Aldrich Corp.

Weighted Average

The change in our estimate of volatility did not result to a material additional expense to our statement of operations.

Revenue recognition: The Company recognizes sales and the related cost of sales at the time the merchandise is shipped to customers or service is performed, when each of the following conditions have been met: an arrangement exists, delivery has occurred, there is a fixed price, and collectability is reasonably assured. Discounts, returns and allowances related to sales, including an estimated reserve for the returns and allowances, are recorded as reduction of revenue.

Shipping and handling fees billed to customers and the cost of shipping and handling fees billed to customers are included in net sales. For the year ending in January 3, 2015, shipping and handling fees billed to customers were approximately $115,000 and the cost of shipping and handling fees billed to customers was approximately $130,000. For the year ending in December 28, 2013, shipping and handling fees billed to customers were approximately $110,000 and the cost of shipping and handling fees billed to customers was approximately $128,000. Shipping and handling fees not billed to customers are recognized as cost of sales.

Taxes collected from customers and remitted to governmental authorities are excluded from revenue, which is presented on a net basis in the statement of operations.

Cash concentration: The Company maintains substantially all of its cash in three different accounts in one bank.

Trade accounts receivable: Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts. Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received.

Other receivables: Other receivables are amounts due for payment to the Company other than the Company’s normal customer invoices for merchandise shipped or services performed. The other receivable amount as of December 28, 2013 was from a legal settlement agreement, which the settlement was reached at arbitration form a lawsuit for the violation of the Company’s trademarks. The counterparty had already remitted the payment to a third party escrow agent prior to December 28, 2013. This payment was deposited by the Company on January 14, 2014. The other receivable amount was recorded as a gain in general and administrative expenses in the statement of operations for the period ended December 28, 2013.

Inventories: Inventories are comprised of raw materials, work-in-process and finished goods. They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market. The inventory on the balance sheet is recorded net of valuation allowances. Labor and overhead has been added to inventory that was manufactured or characterized by the Company. The amounts of major classes of inventory for the periods ended January 3, 2015 and December 28, 2013 are as follows:

2014

2013

Reference standards

1,760,305

1,769,160

Bulk ingredients

2,298,036

694,965

4,058,341

2,464,125

Less valuation allowance

324,000

260,000

3,734,341

2,204,125

Our normal operating cycle for reference standards is currently longer than one year. The Company has approximately 5,000 defined standards and holds a lot of these standards as inventory in small quantities, mostly in grams and milligrams. Due to the large number of different items we carry, certain groups of these reference standards have sales frequency that is slower than others and varies greatly year to year. In addition, for certain reference standards, the cost saving is advantageous when purchased in larger quantities and we have taken advantage of such opportunities when available. Such factors have resulted in an operating cycle to be more than one year on average. The Company gains competitive advantage through the broad offering of reference standards and it is critical for the Company to continue to expand its library of reference standards it offers for the growth of business. Nevertheless, the Company has recently made changes in its reference standards inventory purchasing practice, which the management believes will result in an improved turnover rate and shorter operating cycle without impacting our competitive advantage.

The Company regularly reviews inventories on hand and records a provision for slow-moving and obsolete inventory, inventory not meeting quality standards and inventory subject to expiration. The provision for slow-moving and obsolete inventory is based on current estimates of future product demand, market conditions and related management judgment. Any significant unanticipated changes in future product demand or market conditions that vary from current expectations could have an impact on the value of inventories.

Intangible assets: Intangible assets include licensing rights and are accounted for based on the fair value of consideration given or the fair value of the net assets acquired, whichever is more reliable. Intangible assets with finite useful lives are amortized using the straight-line method over a period of 10 years, or, for licensed patent rights, the remaining term of the patents underlying licensing rights (considered to be the remaining useful life of the license).

Leasehold improvements and equipment: Leasehold improvements and equipment are carried at cost and depreciated on the straight-line method over the lesser of the estimated useful life of each asset or lease term. Leasehold improvements and equipment are comprised of leasehold improvements, laboratory equipment, furniture and fixtures, and computer equipment. Depreciation on equipment under capital lease is included with depreciation on owned assets. Maintenance and repairs are charged to operating expenses as they are incurred. Improvements and betterments, which extend the lives of the assets, are capitalized. Useful lives of leasehold improvements and equipment for each of the category are as follows:

Useful Life

Leasehold improvements

Until the end of the lease term

Computer equipment

3 to 5 years

Furniture and fixtures

7 years

Laboratory equipment

10 years

Long-lived assets are reviewed for impairment on a periodic basis and when changes in circumstances indicate the possibility that the carrying amount may not be recoverable. Long-lived assets are grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets. If the forecast of undiscounted future cash flows is less than the carrying amount of the assets, an impairment charge would be recognized to reduce the carrying value of the assets to fair value. If a possible impairment is identified, the asset group’s fair value is measured relying primarily on a discounted cash flow methodology.

Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method. The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee. Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method. The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary. Evidence of a loss in value might include (i) absence of an ability to recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

Customer deposits and other: Customer deposits and other represent either (i) cash received from customers in advance of product shipment or delivery of services; or (ii) cash received from government as research grants, which the Company has yet to complete the research activities.

The cash received from government as research grants is recognized as a liability until the research is performed. Other than a nominal management fee, which the Company is entitled to earn when the research is performed, the research activities related to the grants are excluded from revenue and are presented on a net basis in the statement of operations.

Income taxes: Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company has not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company files tax returns in all appropriate jurisdictions, which include a federal tax return and various state tax returns. Open tax years for these jurisdictions are 2011 to 2014, which statutes expire in 2015 to 2018, respectively. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in general and administrative expenses in the statements of operations. As of January 3, 2015, the Company has no liability for unrecognized tax benefits.

Research and development costs: Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Research and development costs for the periods ended January 3, 2015 and December 28, 2013 were approximately $514,000 and $134,000, respectively.

Advertising: The Company expenses the production costs of advertising the first time the advertising takes place. Advertising expense for the periods ended January 3, 2015 and December 28, 2013 were approximately $171,000 and $355,000, respectively.

Share-based compensation: The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and non-employees. For employees, share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the period the employee is required to provide services for the award. For non-employees, share-based compensation cost is recorded for all option grants and awards of non-vested stock and is remeasured over the vesting term as earned. The expense is recognized over the period the non-employee is required to provide services for the award.

The Company recognizes compensation expense over the requisite service period using the straight-line method for option grants without performance conditions. For stock options that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method. Compensation expense for stock options with performance conditions is recognized only for those awards expected to vest.

From time to time, the Company awards shares of its common stock to non-employees for services provided or to be provided. The fair value of the awards are measured either based on the fair market value of stock at the date of grant or the value of the services provided, based on which is more reliably measureable. Since these stock awards are fully vested and non-forfeitable, upon issuance the measurement date for the award is usually reached on the date of the award.

Fair Value Measurement: The Company follows the provisions of the accounting standard which defines fair value, establishes a framework for measuring fair value and enhances fair value measurement disclosure. Under these provisions, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

The standard establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use on unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Financial instruments: The estimated fair value of financial instruments has been determined based on the Company’s assessment of available market information and appropriate valuation methodologies. The Company’s financial instruments that are included in current assets and current liabilities are recorded at cost in the consolidated balance sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature.

The carrying amounts reported in the balance sheet for capital lease obligations are present values of the obligations, excluding the interest portion. Capital lease obligations with maturities less than one year are classified as current liabilities.

The carrying amounts reported in the balance sheet for loan payable are present values net of discount, excluding the interest portion. The carrying value of long-term portion of the loan payable approximates fair value because the Company’s interest rate yield based on the credit rating of the Company is believed to be near current market rates. The long-term portion of the Company’s loan payable is considered a Level 3 liability within the fair value hierarchy. Loan payable with maturities less than one year are classified as current liabilities.

Recent accounting standards: In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. On September 27, 2014, the Company early adopted ASU 2014-15. The adoption of ASU 2014-15 had no impacts on the Company’s consolidated financial statements.

Loss_Per_Share_Applicable_to_C

Loss Per Share Applicable to Common Stockholders	12 Months Ended
Loss Per Share Applicable to Common Stockholders	Jan. 03, 2015
Earnings Per Share [Abstract]
Loss Per Share Applicable to Common Stockholders	The following table sets forth the computations of loss per share amounts applicable to common stockholders for the year ended January 3, 2015 and December 28, 2013.

		Years Ended
		2014			2013

	Net loss	$	(5,388,185	)	$	(4,419,525	)

	Basic and diluted loss per common share	$	(0.05	)	$	(0.04	)

	Weighted average common shares outstanding (1):		106,459,379			99,987,443

	Potentially dilutive securities (2):
	Stock options		13,974,052			13,160,955
	Warrants		469,020			-
	Convertible Debt		773,395			-

	(1) Includes 1,623,186 and 500,000 weighted average nonvested shares of restricted stock for the year 2014 and 2013, respectively, which are participating securities that feature voting and dividend rights.

	(2) Excluded from the computation of loss per share as their impact is antidilutive.

Investment_in_Affiliate

Investment in Affiliate	12 Months Ended
Investment in Affiliate	Jan. 03, 2015
Investment In Affiliate
Investment in Affiliate	During the year ended December 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci International Inc. (“NeutriSci”) and consummated the sale of BluScience consumer product line to NeutriSci. The Company used the cost recovery method to account the sale transaction, which was estimated at approximately $3,157,804. The consideration received consisted of following: (a) a $1,000,000 cash payment; (b) a $2,500,000 senior convertible secured note (convertible into 625,000 shares Series I Preferred Stock); and (c) 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci, representing an aggregate of 19% of the NeutriSci shares at the date of the transaction.

	The Company had previously applied the equity method of accounting due to a significant influence that it had obtained from the financial instruments noted above, and the carrying value, which includes the Senior Note, was reflected as long-term investment in affiliate in the Company’s consolidated balance sheet at the date of transaction. The initial carrying value of this investment recognized at the date of transaction was $2,157,804, which is the Company’s unrecovered cost or the difference between the net assets transferred to NeutriSci and the initial monetary consideration received. The 669,708 shares of Series I Preferred Shares and the senior convertible secured note were accounted for as one long-term investment in NeutriSci. Under the cost recovery method, no gain on the sale is recognized until the Company’s cost basis in the net assets transferred has been recovered.

	During the year ended December 28, 2013, the Company received a partial payment of $225,000 for the first installment repayment that was due under the Senior Note.

	Sale of Senior Secured Convertible Note

	On December 30, 2013, the Company assigned the Senior Note to an unrelated third party for $1,250,000. $2,275,000 remained outstanding on the Senior Note at the date of the assignment. The Company also paid legal fees of $7,500 out of the proceeds of the purchase price. The Company also agreed to transfer to the third party a number of shares of preferred stock of NeutriSci having a value of $500,000 upon the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange. There was no recourse provision to the Company associated with the assignment of the note. In connection with the assignment of the note, the Company paid Palladium Capital Advisors, LLC (“Palladium”), a placement agent, a cash fee of $150,000 and agreed to transfer to Palladium a number of shares of preferred stock of NeutriSci having a value of $50,000 upon the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange. The net proceeds received from the assignment of the Senior Note have been charged against the carrying value of the long-term investment in affiliate.

	Sale and Transfer of Preferred Shares

	On December 1, 2014, NeutriSci consummated its reverse merger with Disani Capital Corporation and became listed on Toronto Stock Exchange, TSX Venture Exchange. Immediately prior to NeutriSci’s listing, the Company transferred 108,676 and 10,868 Series I Preferred Shares of NeutriSci to the unrelated third party and Palladium, respectively, pursuant to the terms of the assignment of the Senior Note. In addition, the Company sold the remaining 551,114 Series I Preferred Shares to another unrelated third party for $749,515. The Company recorded a loss of $24,286 as the carrying value prior to these transactions was $773,801. As of January 3, 2015, the Company does not have any investments in NeutriSci.

	Loss of Significant Influence

	As a result of the assignment of the Senior Note described above, the Company no longer had a significant influence on NeutriSci as of December 30, 2013. As a result, the Company discontinued applying equity method of accounting and applied cost method of accounting from December 30, 2013. The adjusted carrying amount as of December 30, 2013 became the new cost figure for the investment and no retrospective adjustments to the financial statements have been made. The Company had elected to record equity method adjustments in losses on the investment in NeutriSci, with a three-month lag, as the financial information of NeutriSci was not available in a timely manner. The equity method adjustment for the previously unaccounted NeutriSci’s operations from October 1, 2013 to December 31, 2013 was recorded during the year ended January 3, 2015, and was incorporated into the adjusted carrying amount of the investment.

	Sales, gross profit, net loss of NeutriSci for the six months ended September 30, 2013 and the three months ended December 31, 2013 are as follows:

		Six Months Ended			Three Months Ended
		30-Sep-13			31-Dec-13
	Sales	$	36,451		$	60,575
	Gross profit		13,310			33,619
	Net loss	$	(813,212	)	$	(435,208	)

	Changes in carrying value and the Company ownership percentage since the inception are summarized as follows:

		Carrying			Ownership
		Value			Percentage
	At March 28, 2013	$	2,157,804			5.7	%

	Company's share of NeutriSci's loss
	through September 30, 2013		(44,961	)
	Proceeds from investment in affiliate		(225,000	)

	At December 28, 2013		1,887,844			4.9	%

	Company's share of NeutriSci's loss
	for the three-month period ended December 31, 2013;
	previously not recognized due to a three-month lag		(21,543	)

	Proceeds from assignment of the Senior Note		(1,092,500	)
	Proceeds from sale and transfer of the Preferred Shares		(749,515	)
	Loss from investment in affiliate		(24,286	)

	At January 3, 2015	$	-			0	%

Intangible_Assets

Intangible Assets	12 Months Ended
Intangible Assets	Jan. 03, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible assets consisted of the following:

		2014				2013
		Gross Carrying		Accumulated		Gross Carrying		Accumulated
		Amount		Amortization		Amount		Amortization
	Amortized intangible assets:
	License agreements and other	$	1,205,275	$	909,224	$	1,075,285	$	873,635


	Amortization expense on amortizable intangible assets included in the consolidated statement of operations for the year ended January 3, 2015 and December 28, 2013 was approximately $36,000 and $24,000, respectively. The unamortized expense is expected to be recognized over a weighted average period of 7.3 years as of January 3, 2015.

	Estimated aggregate amortization expense for each of the next five years is as follows:

	Years ending December:
	2015	$	40,000
	2016		40,000
	2017		40,000
	2018		36,000
	2019		33,000
	Thereafter		107,000
		$	296,000

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	12 Months Ended
Leasehold Improvements and Equipment	Jan. 03, 2015
Leasehold Improvements And Equipment
Leasehold Improvements and Equipment	Leasehold improvements and equipment consisted of the following:

		2014		2013

	Laboratory equipment	$	3,151,748	$	2,782,364
	Leasehold improvements		495,240		491,125
	Computer equipment		329,737		372,851
	Furniture and fixtures		13,039		18,313
	Office equipment		7,877		7,877
	Construction in progress		68,141		40,126
			4,065,782		3,712,656
	Less accumulated depreciation		2,801,122		2,649,417
		$	1,264,660	$	1,063,239

	Depreciation expense on leasehold improvements and equipment included in the consolidated statement of operations for the year ended January 3, 2015 and December 28, 2013 was approximately $223,000 and $246,000, respectively.

	The Company leases equipment under capitalized lease obligations with a total cost of $1,073,601 and $695,461 and accumulated amortization of $242,887 and $136,358 as of January 3, 2015 and December 28, 2013, respectively.

	During the year ended January 3, 2015, the Company disposed of approximately $56,000 of fully depreciated equipment.

Capitalized_Lease_Obligations

Capitalized Lease Obligations	12 Months Ended
Capitalized Lease Obligations	Jan. 03, 2015
Capitalized Lease Obligations
Capitalized Lease Obligations	Minimum future lease payments under capital leases as of January 3, 2015, are as follows:

	Year ending December:
	2015	$	191,454
	2016		178,563
	2017		157,713
	2018		108,860
	2019		33,884
	Total minimum lease payments		670,474
	Less amount representing interest at a rate of approximately 8.8% per year		99,181
	Present value of net minimum lease payments		571,293
	Less current portion		148,278
	Long-term obligations under capital leases	$	423,015

	Interest expense related to capital leases was approximately $47,000 and $34,000 for the years ended January 3, 2015 and December 28, 2013, respectively.

	Subsequent to January 3, 2015, the Company entered into a financing transaction to purchase laboratory equipment. Under the lease terms, the Company will make monthly lease payments, including interest, of approximately $7,000 for 48 months, for a total payment of approximately $356,000. The Company will record a capital lease of approximately $304,000. The equipment will be utilized in our core standards and contract services segment.

Loan_Payable

Loan Payable	12 Months Ended
Loan Payable	Jan. 03, 2015
Debt Disclosure [Abstract]
Loan Payable
	On September 29, 2014, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Technology II, L.P., as lender (“Lender”) and Hercules Technology Growth Capital, Inc., as agent. Lender will provide us with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at closing, and is repayable in equal monthly installments of principal and interest (mortgage style) over 30 months, following an initial interest-only period of twelve months after closing. The remaining $2.5 million of the term loan can be drawn down at our option at any time but no later than July 31, 2015. In connection with the loan, the Company paid a $50,000 facility charge to Lender and recorded as debt issuance cost.

	The term loan bears interest at the rate per year equal to the greater of either (i) 9.35% plus the prime rate as reported in The Wall Street Journal minus 3.25%, or (ii) 9.35%. The Company may prepay all, but no less than all, of the outstanding loan balance, subject to prepayment charges of 3% during the first twelve months following closing, 2% during the next twelve months and 1% thereafter. On the earliest to occur of the (a) the loan maturity date, (b) the date the Company prepays the outstanding loan balance or (c) the date the outstanding loan balance becomes due and payable, the Company will pay Lender an end of term charge equal to 3.75% of all amounts drawn under the loan.

	The Loan Agreement further provides that, subject to certain conditions, any regularly scheduled installment of principal due to Lender may be paid, in whole or in part at the option of the Company or Lender, by converting a portion of the principal of the term loan into shares of the Company’s common stock (the “Conversion Shares”) at a conversion price of $1.293, in lieu of payment in cash. The aggregate principal amount to be paid in Conversion Shares shall not exceed $1,000,000. Of this amount 50% shall convert at the Lender’s option and 50% shall convert at the Company’s option.

	Pursuant to the Loan Agreement, the Company issued Lender a warrant (the “Warrant”) to purchase 419,020 shares of our common stock at an exercise price of $1.062 per share, subject to customary anti-dilution provisions. The Warrant is exercisable and expires five years from the date of issuance.

	In connection with the Loan Agreement, the Company granted first priority liens and security interest in substantially all of our assets, exclusive of intellectual property and 35% of the capital stock of any foreign subsidiary, as collateral for the obligations under the Loan Agreement. The Loan Agreement also contains representations and warranties by the Company and Lender, indemnification provisions in favor of Lender and customary covenants, and events of default. Upon the occurrence of an event of default, a default interest rate of an additional 4% will be applied to the outstanding loan balances, and Lender may terminate its lending commitment, declare all outstanding obligations immediately due and payable, and take such other actions as set forth in the Loan Agreement. We are currently in compliance with all loan covenants.

	Debt Issuance Costs *and End of Term Charge*

	The Company incurred debt issuance costs of $102,866 in connection with this term loan. The debt issuance costs are being amortized as interest expense using the effective interest method over the term of the loan. Amortization of debt issuance costs was $11,505 for the year ended January 3, 2015 and the remaining unamortized debt issuance costs of $91,361 are included in other noncurrent assets. In addition, the Company will pay an end of term charge of $93,750, which is 3.75% of the $2.5 million drawn under the loan. The end of term charge is being accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company accrued $10,486 of this fee during the year ended January 3, 2015.

	Warrant Issued to Lender

	The Company determined the Warrant issued to Lender to be equity classified. The Company estimated the fair value of this Warrant as of the issuance date using a Black-Scholes option pricing model with the following assumptions:

		29-Sep-14
	Fair value of common stock	$	1.08
	Volatility		72.4	%
	Expected dividends		0	%
	Contractual term	5.0 years
	Risk-free rate		1.76	%

	The Company utilized this fair value in its allocation of the loan proceeds between loan payable and the Warrant which was performed on a relative fair value basis. The fair value of the Warrant to purchase 419,020 shares of our common stock was approximately $273,081. Ultimately, the Company allocated $246,189 to the Warrant and recognized this amount in additional paid in capital. Accordingly, this amount is recognized as a debt discount and is being amortized as interest expense using the effective interest method over the term of the loan. Amortization of this debt discount was $27,535 for the year ended January 3, 2015.

	Loan payable as of January 3, 2015 consists of the following:

	Principal amount payable for following years ending December
	2015	$	223,358
	2016		867,247
	2017		1,035,995
	2018		373,400
	Total principal payments		2,500,000
	Accrued end of term charge		10,486
	Total loan payable		2,510,486
	Less unamortized debt discount		218,654
	Less current portion		223,358
	Loan payable – long term	$	2,068,474

	The total interest expenses related the term loan, including cash interest payments, the amortizations of debt issuance costs and debt discount, and the accrual of end of term charge were approximately $112,000 for the year ended January 3, 2015.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Jan. 03, 2015
Income Taxes
Income Taxes	At January 3, 2015 and December 28, 2013, the Company maintained a full valuation allowance against the entire deferred income tax balance which resulted in an effective tax rate of zero for 2014 and 2013. The valuation allowance increased by $2,308,000 as of January 3, 2015.

	A reconciliation of income taxes computed at the statutory Federal income tax rate to income taxes as reflected in the financial statements is summarized as follows:

		2014			2013

	Federal income tax expense at statutory rate		(34.0	)%		(34.0	)%
	State income tax, net of federal benefit		(5.3	)%		(4.3	)%
	Permanent differences		2.7	%		2.6	%
	Change in tax rates		(6.1	)%		(3.7	)%
	Change in valuation allowance		42.8	%		39.2	%
	Other		(0.1	)%		0.2	%
	Effective tax rate		0	%		0	%


	The deferred income tax assets and liabilities consisted of the following components as of January 3, 2015 and December 28, 2013:

		2014			2013

	Deferred tax assets:
	Net operating loss carryforward	$	11,401,000		$	8,953,000
	Stock options and restricted stock		2,934,000			1,945,000
	Investment in affiliate related to BluScience transaction		-			1,187,000
	Inventory reserve		226,000			100,000
	Allowance for doubtful accounts		15,000			3,000
	Accrued expenses		125,000			100,000
	Deferred revenue		4,000			64,000
	Intangibles		26,000			36,000
	Deferred rent		81,000			99,000
			14,812,000			12,487,000
	Less valuation allowance		14,669,000			12,361,000
			143,000			126,000

	Deferred tax liabilities:
	Leasehold improvements and equipment		(108,000	)		(100,000	)
	Prepaid expenses		(35,000	)		(26,000	)
			(143,000	)		(126,000	)

		$	-		$	-

	The Company has tax net operating loss carryforwards and other tax attributes available to offset future federal taxable income and future state taxable income of approximately $28,956,000 and $29,092,000, respectively which begin to expire in the year ending December 31, 2023 and 2015, respectively. The net operating loss can be carried forward up to 20 years for federal tax returns and from 5 to 20 years for various state tax returns. Under the Internal Revenue Code, certain ownership changes may subject the Company to annual limitations on the utilization of its net operating loss carryforward. The Company will continue to analyze the potential impact of any additional transactions undertaken upon the utilization of the net operating losses on a go forward basis.

	The Company has not identified any uncertain tax positions requiring a reserve as of January 3, 2015 and December 28, 2013.

Employee_ShareBased_Compensati

Employee Share-Based Compensation	12 Months Ended
Employee Share-Based Compensation	Jan. 03, 2015
Employee Share-based Compensation
Employee Equity Incentive Plan	Stock Option Plans

	At the discretion of the Company’s compensation committee (the “Compensation Committee”), and with the approval of the Company’s board of directors (the “Board of Directors”), the Company may grant options to purchase the Company’s common stock to certain individuals from time to time. Management and the Compensation Committee determine the terms of awards which include the exercise price, vesting conditions and expiration dates at the time of grant. Expiration dates for stock options are not to exceed 10 years from their date of issuance. The Company, under its Second Amended and Restated 2007 Equity Incentive Plan, is authorized to issue stock options that total no more than 20% of the shares of common stock issued and outstanding, as determined on a fully diluted basis. Beginning in 2007, stock options were no longer issuable under the Company’s 2000 Non-Qualified Incentive Stock Plan. The remaining amount available for issuance under the Second Amended and Restated 2007 Equity Incentive Plan totaled 4,738,496 at January 3, 2015. The stock option awards generally vest ratably over a four-year period following grant date after a passage of time. However, some stock option awards are performance based and vest based on the achievement of certain criteria established by the Compensation Committee, subject to approval by the Board of Directors.

	The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes based option valuation model. The table below outlines the weighted average assumptions for options granted to employees during the years ended January 3, 2015 and December 28, 2013.

	Year Ended December		2014				2013
	Expected Volatility			74.63	%			32.75	%
	Expected dividends			0	%			0	%
	Expected term		5.76 years				6.0 years
	Risk-free rate			1.86	%			1.51	%

	Prior to the year 2014, the Company calculated expected volatility from the volatility of publicly held companies in similar industries, as the historical volatility of the Company’s common stock did not cover the period equal to the expected life of the options. For the stock options granted during the year ended January 3, 2015, the Company calculated expected volatility rate based principally on the combined volatility of similarly situated publicly held companies. Based on the expected term of stock options, a 20~75% weight was assigned to the volatility of the Company common stock as the historical volatility of the Company’s common stock from June 2008 through April 2010 was exceptionally high due to a thinly traded market. Below table illustrates the Company’s historical volatility and the average daily trading volume of the Company’s common stock from June 2008 through April 2010 and from April 2010 through December 2014.

	Period		Volatility				Average Daily
	Period		Volatility				Trading Volume
	6/20/2008 ~ 4/19/2010			402	%			11,455
	4/20/2010 ~ 1/2/2015			77	%			155,111

	The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term. For the expected term, the Company used SEC Staff Accounting Bulletin No. 107 simplified method since most of the options granted were “plain vanilla” options with following characteristics: (i) the share options are granted at the market price on the grant date; (ii) exercisability is conditional on performing service through the vesting date on most options; (iii) If an employee terminates service prior to vesting, the employee would forfeit the share options; (iv) if an employee terminates service after vesting, the employee would have 30 days to exercise the share options; and (v) the share options are nontransferable and nonhedgeable.

	1) Service Period Based Stock Options


	The majority of options granted by the Company are comprised of service based options granted to employees. These options vest ratably over a defined period following grant date after a passage of a service period.

	The following table summarizes service period based stock options activity at January 3, 2015 and changes during the year then ended:

							Weighted Average
										Remaining		Aggregate
			Number of				Exercise			Contractual		Intrinsic
			Shares				Price			Term		Value
	Outstanding at December 28, 2013			12,113,655			$	1.06			7.43

	Options Granted			2,233,987				1.39			10
	Options Classification from Employee to Non-Employee			(113,151	)			0.76
	Options Exercised			(534,715	)			0.87
	Options Expired			(253,900	)			1
	Options Forfeited			(722,275	)			1.13
	Outstanding at January 3, 2015			12,723,601			$	1.13			7	$	581,050

	Exercisable at January 3, 2015			9,362,374			$	1.13			6.4	$	455,570

	The aggregate intrinsic values in the table above are based on the Company’s closing stock price of $0.90 on the last day of business for the year ended January 3, 2015. The weighted average fair value of options granted during the years ended January 3, 2015, and December 28, 2013 was $0.90, and $0.29 respectively. The aggregate intrinsic value for options exercised during the years ended January 3, 2015, and December 28, 2013 was approximately $156,000 and $7,000 respectively.

	2) Performance Based Stock Options

	The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee. If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.

	The following table summarizes performance based stock options activity at January 3, 2015 and changes during the year then ended:

							Weighted Average
										Remaining		Aggregate
			Number of				Exercise			Contractual		Intrinsic
			Shares				Price			Term		Value
	Outstanding at December 28, 2013			200,000			$	0.63			9.08

	Options Granted			-				-
	Options Exercised			-				-
	Options Expired			-				-
	Options Forfeited			-				-
	Outstanding at January 3, 2015			200,000			$	0.63			8.08	$	54,000

	Exercisable at January 3, 2015			95,833			$	0.63			8.08	$	25,875

The aggregate intrinsic value in the table above are, based on the Company’s closing stock price of $0.90 on the last day of business for the period ended January 3, 2015.

As of January 3, 2015, there was approximately $1,768,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options. That cost is expected to be recognized over a weighted average period of 2.20 years. The realized tax benefit from stock options for the years ended January 3, 2015, and December 28, 2013 was $0, based on the Company’s election of the “with and without” approach.

Restricted Stock Awards

Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award.

The following table summarizes activity of restricted stock awards granted to employees at January 3, 2015 and changes during the year then ended:

						Weighted Average
						Award-Date
		Shares				Fair Value
Unvested shares at December 28, 2013			500,000			$	0.69

Granted			1,090,000				1.41
Vested			-				-
Forfeited			-				-
Unvested shares at January 3, 2015			1,590,000			$	1.18

Expected to Vest as of January 3, 2015			1,590,000			$	1.18

On January 2, 2014, the Company awarded an aggregate of 1,090,000 shares of restricted stock to the Company’s officers and members of the board of directors. These shares shall vest upon the earlier to occur of the following: (i) the market price of the Company’s stock exceeds a certain price, or (ii) one of other certain triggering events, including the termination of the officers and members of the board of directors without cause for any reason. The fair values of these restricted stock awards were $1,536,900 in aggregate, and they were based on the trading price of the Company’s common stock on the date of grant. The expense related to the restricted stock award has been amortized over the period of six months through July 1, 2014, as the Company determined the requisite service period to be 6 months as that is when they are eligible to vest.

Employee Option and Restricted Stock Compensation

The Company recognized share-based compensation expense of approximately $2,747,000 and $958,000 in general and administrative expenses in the statement of operations for the year ended January 3, 2015 and December 28, 2013.

NonEmployee_ShareBased_Compens

Non-Employee Share-Based Compensation	12 Months Ended
Non-Employee Share-Based Compensation	Jan. 03, 2015
Non-employee Share-based Compensation
Non-Employee Share-Based Compensation [Text Block]	Stock Option Plan

	At the discretion of management, working with the Compensation Committee, and with approval of the Board of Directors, the Company may grant options to purchase the Company’s common stock to certain individuals from time to time who are not employees of the Company. These options are granted under the Second Amended and Restated 2007 Equity Incentive Plan of the Company and are granted on the same terms as those being issued to employees. Stock options granted to non-employees are accounted for using the fair value approach. The fair value of non-employee option grants are estimated using the Black-Scholes option-pricing model and are re-measured over the vesting term until earned. The estimated fair value is expensed over the applicable service period.

	The following table summarizes activity of stock options granted to non-employees at January 3, 2015 and changes during the year then ended:

					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 28, 2013		847,300		$	1.44		5.74

	Options Granted		90,000			1.24		10
	Options Classification from Employe to Non-Employee		113,151			0.76
	Options Exercised		-			-
	Options Forfeited		-			-
	Outstanding at January 3, 2015		1,050,451		$	1.35		5.46	$	37,550

	Exercisable at January 3, 2015		971,701		$	1.36		5.12	$	37,550

	The aggregate intrinsic values in the table above are, based on the Company’s closing stock price of $0.90 on the last day of business for the year ended January 3, 2015. The aggregate intrinsic value for options exercised during the year ended December 28, 2013 was $35,000.

	As of January 3, 2015, there was approximately $44,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plan for non-employee stock options. The unrecognized compensation expense is expected to be recognized over a weighted average period of 1.7 years.

	Stock Awards

	On July 1, 2014, the Company awarded 65,000 shares of the Company’s common stock that were fully vested and non-forfeitable to a non-employee. The fair value of the award, which amounted to $83,850 was based on the trading price of the Company’s stock on the date of grant. The expense related to this stock award is being amortized over the period of approximately 7 months, as the services relating to this award are being provided over this period of time. In addition, there were stock awards made in 2013, which the Company has recognized a portion of the expense in 2014 as the required service periods extended into 2014. The total expense the Company recognized for stock awards to non-employees was approximately $129,000 for the twelve months ended January 3, 2015. During the twelve months ended December 28, 2013, the Company awarded an aggregate of 600,000 shares and recognized a total expense of approximately $325,000.

	As of January 3, 2015, there was approximately $11,000 of total unrecognized compensation expense related to the stock award to a non-employee. That cost is expected to be recognized over a period of approximately one month.

	Warrant Awards

	On October 27, 2014, the Company awarded a warrant to purchase 50,000 shares of the Company’s common stock to a certain non-employee. The exercise price of the warrant was $1.10 per share and the term of the warrant was 2 years. The fair value of the warrant was estimated at the date of award using the Black-Scholes based valuation model. The table below outlines the assumptions for the warrant granted.

		27-Oct-14
	Volatility		66.9	%
	Expected dividends		0	%
	Contractual term	2.0 years
	Risk-free rate		0.41	%

	The Company calculated expected volatility from the historical volatility of Company’s common stock. The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term. The expected term of the warrants represents the contractual terms. For the year ended January 3, 2015, the expense the Company recognized for this warrant award was approximately $6,000. As of January 3, 2015, there was approximately $10,000 of total unrecognized compensation expense related to this warrant, expected to be recognized over a period of approximately 4 months.

	During the year ended December 28, 2013, the Company recognized an expense of approximately $4,000 for the warrant that was previously awarded to a certain non-employee on August 7, 2012. On December 9, 2013, the warrant was exercised and the Company issued 74,186 shares of common stock. The non-employee who held the warrant elected a cashless exercise pursuant to the provisions of the warrant and received 74,186 shares of common stock in lieu of 250,000 shares for a cash payment of $0.75 per share. The intrinsic value of the warrant exercised was $90,507.

	Restricted Stock Award

	Restricted stock awards granted by the Company to non-employees generally feature time vesting service conditions, specified in the respective service agreements. Restricted stock awards issued to non-employees are accounted for at current fair value through the vesting period. The fair value of vested non-employee restricted shares awarded during the twelve months ended January 3, 2015 was approximately $24,000, which represents the market value of the Company’s common stock on respective vesting dates charged to expense.

	The following table summarizes activity of restricted stock awards issued to non-employees at January 3, 2015 and changes during the year then ended:

					Weighted Average
		Shares			Fair Value
	Unvested shares at December 28, 2013		-		$	-

	Granted		96,000			1.3
	Vested		(20,000	)		1.17
	Forfeited		-			-
	Unvested shares expected to vest at January 3, 2015		76,000		$	0.9

	As of January 3, 2015, there was approximately $68,000 of total unrecognized compensation expense related to the restricted stock award to a non-employee. That cost is expected to be recognized over a period of 3.2 years as of January 3, 2015.

	Non-Employee Option, Stock, Warrant and Restricted Stock Awards

	For non-employee share-based compensation, the Company recognized share-based compensation expense of approximately $170,000 and $330,000 in general and administrative expenses in the statement of operations for the year ended January 3, 2015 and December 28, 2013.

Stock_Issuance

Stock Issuance	12 Months Ended
Stock Issuance	Jan. 03, 2015
Stock Issuance
Stock Issuance	On June 11, 2014, the Company issued 44,605 shares of common stock to a vendor to settle an outstanding payable balance of $52,188.

	On June 18, 2014, the Company issued 82,000 shares of common stock to a vendor to settle an outstanding payable balance of $76,306 and payment of 6 months of $3,000 per month monthly retainer fees from July 2014 through December 2014.

	In Fiscal Year 2013, the Company sold approximately 3.5 million shares with gross proceeds of approximately $3.0 million to two strategic accredited investors pursuant to a subscription agreement. A total placement agent fee of $20,000 was incurred in connection with the investments.

Warrants

Warrants	12 Months Ended
Warrants	Jan. 03, 2015
FairValueAssumptionsRiskFreeInterestRateStockIssuance
Warrants	The following table summarizes activity of warrants at January 3, 2015 and December 28, 2013 and changes during the years then ended:

					Weighted Average
							Remaining			Aggregate
		Number of			Exercise		Contractual			Intrinsic
		Shares			Price		Term			Value
	Outstanding at December 29, 2012		10,056,914		$	0.72		0.44

	Warrants Issued
	Warrants Exercised		(8,338,564	)		0.25
	Warrants Expired		(1,718,350	)		3
	Outstanding at December 28, 2013		-			-

	Warrants Issued		469,020			1.07		4.68
	Warrants Exercised		-			-
	Warrants Expired		-			-
	Outstanding and exercisable at January 3, 2015		469,020		$	1.07		4.43	$	-

	The aggregate intrinsic values in the table above are based on the Company’s closing stock price of $0.90 on the last day of business for the year ended January 3, 2015.

	On September 29, 2014, the Company issued Hercules Technology II, L.P. a warrant to purchase 419,020 shares of the Company’s common stock at an exercise price of $1.062 per share pursuant to the Loan Agreement. This warrant has not been exercised as of January 3, 2015.

	On October 27, 2014, the Company awarded a certain non-employee a warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $1.10 per share. This warrant has not been exercised as of January 3, 2015.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jan. 03, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Lease

	The Company leases its office and research facilities in California, Colorado and Maryland under operating lease agreements that expire at various dates from August 2015 through September 2019. Monthly lease payments range from $1,320 per month to $22,788 per month, and minimum lease payments escalate during the terms of the leases. Generally accepted accounting principles require total minimum lease payments to be recognized as rent expense on a straight-line basis over the term of the lease. The excess of such expense over amounts required to be paid under the lease agreement is carried as a liability on the Company’s consolidated balance sheet.

	Minimum future rental payments under all of the leases are as follows:

	Fiscal years ending:
	2015	$	544,000
	2016		319,000
	2017		225,000
	2018		233,000
	2019		181,000
		$	1,502,000
	Rent expense was approximately $537,000, and $519,000 for the years ended January 3, 2015 and December 28, 2013, respectively.

	Royalty

	The Company has 10 licensing agreements with leading research universities, pursuant to which the Company acquired patents related to certain products the Company offers to its customers. These agreements afford for future royalty payments based on contractual minimums and expire at various dates from December 31, 2019 through April 12, 2032. Yearly minimum royalty payments including license maintenance fees range from $5,000 per year to $50,000 per year, however, these minimum payments escalate each year with a maximum of $150,000 per year. In addition, the Company is required to pay a range of 2% to 5% of sales related to the licensed products under these agreements. Total royalty expense including license maintenance fees from continuing operations for the year ended January 3, 2015 and December 28, 2013 was approximately $323,000 and $111,000, respectively under these agreements. Minimum royalties including license maintenance fees for the next five years are as follows:

	Fiscal years ending:
	2015	$	272,000
	2016		283,000
	2017		320,000
	2018		338,000
	2019		339,000
		$	1,552,000

	Legal proceedings

	The Company from time to time is involved in legal proceedings in the ordinary course of our business, which can include employment claims, product claims and patent infringements. We do not believe that any of these claims and proceedings against us as they arise are likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.

	Severance payments to executive officers

	As of January 3, 2015, the Company has three executive officers, Frank Jaksch, Jr., Chief Executive Officer, Thomas Varvaro, Chief Financial Officer and Troy A. Rhonemus, Chief Executive Officer. Upon termination, Mr. Jaksch, Mr. Varvaro and Mr. Rhonemus will receive severance payments per the terms of the respective employment agreements entered with the Company. The key terms of the employment agreements, including the severance terms are as follows:

	Employment Agreement with Frank L. Jaksch Jr.

	On April 19, 2010, the Company entered into an Amended and Restated Employment Agreement (the “Amended Jaksch Agreement”) with Frank L. Jaksch Jr. The Amended Jaksch Agreement has a three year term, beginning on the date of the Agreement that automatically renews unless the Amended Jaksch Agreement is terminated in accordance with its terms. On January 2, 2014, the Board approved the recommendations of the Company’s Compensation Committee raising the annual base salary of Mr. Jaksch to $275,000 per year and raising the annual cash bonus target for Mr. Jaksch up to 50% of his base salary.

	The severance terms of the Amended Jaksch Agreement provide that in the event Mr. Jaksch’s employment with the Company is terminated voluntarily by Mr. Jaksch, he will be entitled to any accrued but unpaid base salary, any stock vested through the date of his termination and a pro-rated portion of 50% of his salary (50% of his salary being the “Maximum Annual Bonus”) for the year of termination. In addition, if Mr. Jaksch leaves the Company for “Good Reason”, (as defined in the Amended Jaksch Agreement), he will also be entitled to severance equal to the Maximum Annual Bonus, and he will be deemed to have been employed for the entirety of such year. Severance will then consist of 16 weeks of paid salary, unless Mr. Jaksch signs a release, in which case he will receive compensation equal to the lesser of the remainder of the term of the agreement, or up to 12 months paid salary.

	In the event the Company terminates Mr. Jaksch’s employment “without Cause” (as defined in the Amended Jaksch Agreement), Mr. Jaksch will be entitled to severance in the form of any stock vested through the date of his termination and continuation of his base salary for a period of eight weeks, or, if Mr. Jaksch enters into a standard separation agreement, Mr. Jaksch will receive continuation of base salary and health benefits, together with applicable fringe benefits as provided to other executive employees until the last to occur of the expiration of the term or renewal term then in effect or 24 months from the date of termination (the “Severance Period”), and he will receive his Maximum Annual Bonus if the Severance Period is equal to 24 months or a pro rata portion thereof if less, as well as the full vesting of any otherwise unvested stock.

	Employment Agreement with Thomas C. Varvaro

	On April 19, 2010, the Company entered into an Amended and Restated Employment Agreement (the “Amended Varvaro Agreement”) with Thomas C. Varvaro. The Amended Varvaro Agreement has a three year term beginning on the date of the agreement that automatically renews unless the Amended Varvaro Agreement is terminated in accordance with its terms. On January 2, 2014, the Board approved the recommendations of the Company’s Compensation Committee raising the annual base salary of Mr. Varvaro to $225,000 per year and raising the annual cash bonus target for Mr. Varvaro up to 40% of his base salary.

	The severance terms of the Amended Varvaro Agreement provide that in the event Mr. Varvaro’s employment with us is terminated voluntarily by Mr. Varvaro he will be entitled to any accrued but unpaid base salary, any stock vested through the date of his termination and a pro-rated portion of 40% of his salary (40% of this salary being the “Maximum Annual Bonus”) for the year of termination. In addition, if Mr. Varvaro leaves the Company for “Good Reason” (as defined in the Amended Varvaro Agreement), he will also be entitled to severance equal to the Maximum Annual Bonus, and he shall be deemed to have been employed for the entirety of such year. Severance will then consist of 16 weeks of paid salary, unless Mr. Varvaro signs a release, in which case he will receive compensation equal to the lesser of the remainder of his agreement or 12 months paid salary.

	In the event the Company terminates Mr. Varvaro’s employment “without Cause,” Mr. Varvaro will be entitled to severance in the form of any stock vested through the date of his termination and continuation of his base salary for a period of eight weeks, or, if Mr. Varvaro enters into a standard separation agreement, Mr. Varvaro will receive continuation of base salary and health benefits, together with applicable fringe benefits as provided to other executive employees until the last to occur of the expiration of the term or renewal term then in effect or 24 months from the date of termination (the “Severance Period”), will receive his Maximum Annual Bonus if the Severance Period is equal to 24 months or a pro rata portion thereof if less, as well as the full vesting of any otherwise unvested stock.

	Employment Agreement with Troy A. Rhonemus

	On March 6, 2014, the Company entered into an Employment Agreement (the “Rhonemus Agreement”) with Mr. Troy Rhonemus pursuant to which Mr. Rhonemus was appointed to serve as the Chief Operating Officer of the Company. The Rhonemus Agreement provides for a base salary of $180,000, and provides for an annual cash bonus (based on performance targets) of up to 30% of his base salary (30% of this salary being the “Maximum Annual Bonus”), and provides for option grants of 250,000 shares of Common Stock. The option grants were awarded on February 21, 2014 at an exercise price of $1.75 per share, which vest 33% one year from the date of grant with the remainder vesting in 24 equal monthly installments thereafter.

	Upon termination, Mr. Rhonemus will be entitled to any accrued but unpaid base salary and any accrued but unpaid welfare and retirement benefits up to the termination date. In addition, if Mr. Rhonemus leaves the Company for “Good Reason” (as defined in the Rhonemus Agreement), he will also be entitled to severance equal to two weeks of base salary for each full year of service to a maximum of eight weeks of the base salary.

	In the event the Company terminates Mr. Rhonemus’ employment “without Cause,” Mr. Rhonemus will be entitled to severance equal to two weeks of base salary for each full year of service to a maximum of eight weeks of the base salary, or, if Mr. Rhonemus enters into a standard separation agreement, Mr. Rhonemus will receive continuation of base salary and health benefits, together with applicable fringe benefits as provided until the expiration of the term or renewal term then in effect, however, that in the case of medical and dental insurance, until the expiration of 12 months from the date of termination.

Business_Segmentation_and_Geog

Business Segmentation and Geographical Distribution	12 Months Ended
Business Segmentation and Geographical Distribution	Jan. 03, 2015
Business Segmentation And Geographical Distribution
Business Segmentation and Geographical Distribution	Since the year ended December 28, 2013, the Company has generated significant revenue from its ingredients operations and has made operational changes, including changes in the organizational structure to support the ingredients operations. As a result, on December 29, 2013, the Company began segregating its financial results for ingredients operations, and has following three reportable segments.

		·	Core standards, and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, reference materials, and related contract services.

		·	Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries including the nutritional supplement, food and beverage and animal health industries.

		·	Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.

	The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.

	Year ended		Core Standards and		Ingredients		Regulatory		Other			Total
	3-Jan-15		Contract Services		segment		Consulting segment
			segment

	Net sales		$	7,487,189	$	6,857,177	$	968,813	$	-		$	15,313,179
	Cost of sales			5,141,667		4,257,347		588,500		-			9,987,514

	Gross profit			2,345,522		2,599,830		380,313		-			5,325,665

	Operating expenses:
	Sales and marketing			975,800		1,081,209		79,575		-			2,136,584
	General and administrative			-		-		-		8,374,601			8,374,601
	Loss from investment in affiliate			-		-		-		45,829			45,829
	Operating expenses			975,800		1,081,209		79,575		8,420,430			10,557,014

	Operating income (loss)		$	1,369,722	$	1,518,621	$	300,738	$	(8,420,430	)	$	(5,231,349	)

	Year ended		Core Standards and		Ingredients		Scientific and		Other			Total
	28-Dec-13		Contract		segment		Regulatory
			Services				Consulting segment
			segment

	Net sales		$	6,643,832	$	2,430,699	$	1,146,718	$	(60,285	)	$	10,160,964
	Cost of sales			4,893,649		1,501,187		632,037		955			7,027,828

	Gross profit (loss)			1,750,183		929,512		514,681		(61,240	)		3,133,136

	Operating expenses:
	Sales and marketing			1,459,620		752,121		14,705		131,159			2,357,605
	General and administrative			-		-		-		5,117,016			5,117,016
	Loss from investment in affiliate			-		-		-		44,961			44,961
	Operating expenses			1,459,620		752,121		14,705		5,293,136			7,519,582

	Operating income (loss)		$	290,563	$	177,391	$	499,976	$	(5,354,376	)	$	(4,386,446	)


	At January 3, 2015		Core Standards and		IngrediEnts		Scientific and		Other			Total
			Contract Services		segment		Regulatory
			segment				Consulting
							segment

	Total assets		$	3,220,518	$	3,757,073	$	105,711	$	4,524,906		$	11,608,208



	At December 28, 2013		Core Standards and		Ingredients		Scientific and		Other			Total
			Contract		segment		Regulatory
			Services				Consulting segment
			segment

	Total assets		$	2,952,270	$	1,083,856	$	139,765	$	4,811,001		$	8,986,892


	Revenue from international sources for the core standards and contract services segment approximated $1,756,000 and $1,488,000 for the years ended January 3, 2015 and December 28, 2013, respectively. Revenues from international sources for the ingredients segment approximated $35,000 and $22,000 for the years ended January 3, 2015 and December 28, 2013, respectively. Revenues from international sources for the scientific and regulatory consulting segment approximated $104,000 and $450,000 for the years ended January 3, 2015 and December 28, 2013, respectively. International sources which the Company generates revenue include Europe, North America, South America, Asia, and Oceania.

The Company’s long-lived assets are located within the United States.

Subsequent_Events

Subsequent Events	12 Months Ended
	Jan. 03, 2015
Subsequent Events [Abstract]
Subsequent Events	On January 28, 2015, the Company awarded 350,000 shares of common stock to consultants for certain investor relations services to be provided.

	On February 25, 2015, the Board of Directors (the “Board”) appointed Stephen Allen, a current Board member, to serve as Chairman of the Board. Mr. Allen remained on the Board’s Compensation Committee and chairperson of the Board’s Nominating and Corporate Governance Committee.

	Also on February 25, 2015, Michael Brauser and Barry Honig, who were Co-Chairmen of the Board of Directors (the “Board”) of the Company, resigned from the Board. Mr. Brauser’s and Mr. Honig’s resignations were not a result of any disagreements with the Company’s operations, policies or practices. At the time of resignation, Mr. Brauser and Mr. Honig held following unvested securities of the Company:

		·	Michael Brauser – 26,667 stock options at an exercise price of $1.25 per share; 250,000 shares of restricted stock.

		·	Barry Honig – 26,667 stock options at an exercise price of $1.25 per share; 250,000 shares of restricted stock.

	The Board made a resolution that above unvested securities are immediately vested on the date of resignation. In addition, the Board made a resolution that all stock options held by Mr. Brauser and Mr. Honig will expire in accordance with their terms as if Mr. Brauser and Mr. Honig remained directors of the Company.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)

12 Months Ended

Jan. 03, 2015

Accounting Policies [Abstract]

Basis of presentation

Use of and Changes in Accounting estimates

Period

Volatility

Average Daily

Trading Volume

6/20/2008 ~ 4/19/2010

402

11,455

4/20/2010 ~ 1/2/2015

155,111

The following is a pro-forma disclosure of our historical calculation of estimated volatility over the expected term based on a grant with an expected term of 6 years:

Fiscal Year 2013

Name

Use

Volatility

Name

Use

Volatility

Covance, Inc.

ChromaDex Corp.

243

Sigma-Aldrich Corp.

Covance Inc.

Sigma-Aldrich Corp.

Weighted Average

The change in our estimate of volatility did not result to a material additional expense to our statement of operations.

Revenue recognition

Taxes collected from customers and remitted to governmental authorities are excluded from revenue, which is presented on a net basis in the statement of operations.

Cash concentration

Cash concentration: The Company maintains substantially all of its cash in three different accounts in one bank.

Trade accounts receivable

Other receivables

Inventories

2014

2013

Reference standards

1,760,305

1,769,160

Bulk ingredients

2,298,036

694,965

4,058,341

2,464,125

Less valuation allowance

324,000

260,000

3,734,341

2,204,125

Intangible assets

Leasehold improvements and equipment

Useful Life

Leasehold improvements

Until the end of the lease term

Computer equipment

3 to 5 years

Furniture and fixtures

7 years

Laboratory equipment

10 years

Long-term investment in affiliate

Customer deposits and other

Income taxes

Research and development costs

Advertising

Share-based compensation

Fair Value Measurement

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Financial instruments

Recent accounting standards:

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
Significant Accounting Policies (Tables)	Jan. 03, 2015
Accounting Policies [Abstract]
Historical volatility and the average daily trading volume of the Companybs common stock
	Period		Volatility			Average Daily
	Period		Volatility			Trading Volume
	6/20/2008 ~ 4/19/2010			402	%		11,455
	4/20/2010 ~ 1/2/2015			77	%		155,111


Pro-forma disclosure of our historical calculation of estimated volatility	Fiscal Year 2013								Fiscal Year 2013
	Name		Use			Volatility			Name	Use			Volatility
	Covance, Inc.			50	%		35	%	ChromaDex Corp.		20	%		243	%
	Sigma-Aldrich Corp.			50	%		30	%	Covance Inc.		40	%		35	%
									Sigma-Aldrich Corp.		40	%		30	%
	Weighted Average						33	%	Weighted Average					75	%

Inventories			2014			2013
	Reference standards		$	1,760,305		$	1,769,160
	Bulk ingredients			2,298,036			694,965
				4,058,341			2,464,125
	Less valuation allowance			324,000			260,000
			$	3,734,341		$	2,204,125
Leasehold improvements and equipment		Useful Life
	Leasehold improvements	Until the end of the lease term
	Computer equipment	3 to 5 years
	Furniture and fixtures	7 years
	Laboratory equipment	10 years

Loss_Per_Share_Applicable_to_C1

Loss Per Share Applicable to Common Stockholders (Tables)	12 Months Ended
Loss Per Share Applicable to Common Stockholders (Tables)	Jan. 03, 2015
Earnings Per Share Tables
Earnings Per Share		Years Ended
		2014			2013

	Net loss	$	(5,388,185	)	$	(4,419,525	)

	Basic and diluted loss per common share	$	(0.05	)	$	(0.04	)

	Weighted average common shares outstanding (1):		106,459,379			99,987,443

	Potentially dilutive securities (2):
	Stock options		13,974,052			13,160,955
	Warrants		469,020			-
	Convertible Debt		773,395			-

	(1) Includes 1,623,186 and 500,000 weighted average nonvested shares of restricted stock for the year 2014 and 2013, respectively, which are participating securities that feature voting and dividend rights.

	(2) Excluded from the computation of loss per share as their impact is antidilutive.

Investment_in_Affiliate_Tables

Investment in Affiliate (Tables)	12 Months Ended
Investment in Affiliate (Tables)	Jan. 03, 2015
Investment In Affiliate
NeutriSci Business information		Six Months Ended			Three Months Ended
		30-Sep-13			31-Dec-13
	Sales	$	36,451		$	60,575
	Gross profit		13,310			33,619
	Net loss	$	(813,212	)	$	(435,208	)

Change in Carrying Value and Ownership		Carrying			Ownership
		Value			Percentage
	At March 28, 2013	$	2,157,804			5.7	%

	Company's share of NeutriSci's loss
	through September 30, 2013		(44,961	)
	Proceeds from investment in affiliate		(225,000	)

	At December 28, 2013		1,887,844			4.9	%

	Company's share of NeutriSci's loss
	for the three-month period ended December 31, 2013;
	previously not recognized due to a three-month lag		(21,543	)

	Proceeds from assignment of the Senior Note		(1,092,500	)
	Proceeds from sale and transfer of the Preferred Shares		(749,515	)
	Loss from investment in affiliate		(24,286	)

	At January 3, 2015	$	-			0	%

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Jan. 03, 2015
Intangible Assets Tables
Intangible assets		2014				2013
		Gross Carrying		Accumulated		Gross Carrying		Accumulated
		Amount		Amortization		Amount		Amortization
	Amortized intangible assets:
	License agreements and other	$	1,205,275	$	909,224	$	1,075,285	$	873,635
Estimated aggregate amortization expense	Years ending December:
	2015	$	40,000
	2016		40,000
	2017		40,000
	2018		36,000
	2019		33,000
	Thereafter		107,000
		$	296,000

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	12 Months Ended
Leasehold Improvements and Equipment (Tables)	Jan. 03, 2015
Leasehold Improvements And Equipment
Leasehold Improvements and Equipment		2014		2013

	Laboratory equipment	$	3,151,748	$	2,782,364
	Leasehold improvements		495,240		491,125
	Computer equipment		329,737		372,851
	Furniture and fixtures		13,039		18,313
	Office equipment		7,877		7,877
	Construction in progress		68,141		40,126
			4,065,782		3,712,656
	Less accumulated depreciation		2,801,122		2,649,417
		$	1,264,660	$	1,063,239

Capitalized_Lease_Obligations_

Capitalized Lease Obligations (Tables)	12 Months Ended
Capitalized Lease Obligations (Tables)	Jan. 03, 2015
Capitalized Lease Obligations Tables
Minimum future lease payments	Year ending December:
	2015	$	191,454
	2016		178,563
	2017		157,713
	2018		108,860
	2019		33,884
	Total minimum lease payments		670,474
	Less amount representing interest at a rate of approximately 8.8% per year		99,181
	Present value of net minimum lease payments		571,293
	Less current portion		148,278
	Long-term obligations under capital leases	$	423,015

Loan_Payable_Tables

Loan Payable (Tables)	12 Months Ended
Loan Payable (Tables)	Jan. 03, 2015
Debt Disclosure [Abstract]
Fair value assumptions		29-Sep-14
	Fair value of common stock	$	1.08
	Volatility		72.4	%
	Expected dividends		0	%
	Contractual term	5.0 years
	Risk-free rate		1.76	%
Loan Payable, Principal amount payable	Principal amount payable for following years ending December
	2015	$	223,358
	2016		867,247
	2017		1,035,995
	2018		373,400
	Total principal payments		2,500,000
	Accrued end of term charge		10,486
	Total loan payable		2,510,486
	Less unamortized debt discount		218,654
	Less current portion		223,358
	Loan payable – long term	$	2,068,474

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Jan. 03, 2015
Income Taxes Tables
Reconciliation of income tax expense (benefit)		2014			2013

	Federal income tax expense at statutory rate		(34.0	)%		(34.0	)%
	State income tax, net of federal benefit		(5.3	)%		(4.3	)%
	Permanent differences		2.7	%		2.6	%
	Change in tax rates		(6.1	)%		(3.7	)%
	Change in valuation allowance		42.8	%		39.2	%
	Other		(0.1	)%		0.2	%
	Effective tax rate		0	%		0	%

Deferred income tax assets and liabilities		2014			2013

	Deferred tax assets:
	Net operating loss carryforward	$	11,401,000		$	8,953,000
	Stock options and restricted stock		2,934,000			1,945,000
	Investment in affiliate related to BluScience transaction		-			1,187,000
	Inventory reserve		226,000			100,000
	Allowance for doubtful accounts		15,000			3,000
	Accrued expenses		125,000			100,000
	Deferred revenue		4,000			64,000
	Intangibles		26,000			36,000
	Deferred rent		81,000			99,000
			14,812,000			12,487,000
	Less valuation allowance		14,669,000			12,361,000
			143,000			126,000

	Deferred tax liabilities:
	Leasehold improvements and equipment		(108,000	)		(100,000	)
	Prepaid expenses		(35,000	)		(26,000	)
			(143,000	)		(126,000	)

		$	-		$	-

Employee_ShareBased_Compensati1

Employee Share-Based Compensation (Tables)	12 Months Ended
Employee Share-Based Compensation (Tables)	Jan. 03, 2015
Employee Share-based Compensation Tables
Weighted average assumptions of stock options granted	Year Ended December	2014			2013
	Expected Volatility		74.63	%		32.75	%
	Expected dividends		0	%		0	%
	Expected term	5.76 years			6.0 years
	Risk-free rate		1.86	%		1.51	%
Historical volatility and the average daily trading volume of the Companybs common stock
	Period	Volatility			Average Daily
	Period	Volatility			Trading Volume
	6/20/2008 ~ 4/19/2010		402	%		11,455
	4/20/2010 ~ 1/2/2015		77	%		155,111


Service Period Based Stock Options					Weighted Average
								Remaining		Aggregate
		Number of			Exercise			Contractual		Intrinsic
		Shares			Price			Term		Value
	Outstanding at December 28, 2013		12,113,655		$	1.06			7.43

	Options Granted		2,233,987			1.39			10
	Options Classification from Employee to Non-Employee		(113,151	)		0.76
	Options Exercised		(534,715	)		0.87
	Options Expired		(253,900	)		1
	Options Forfeited		(722,275	)		1.13
	Outstanding at January 3, 2015		12,723,601		$	1.13			7	$	581,050

	Exercisable at January 3, 2015		9,362,374		$	1.13			6.4	$	455,570
Performance Based Stock Options					Weighted Average
								Remaining		Aggregate
		Number of			Exercise			Contractual		Intrinsic
		Shares			Price			Term		Value
	Outstanding at December 28, 2013		200,000		$	0.63			9.08

	Options Granted		-			-
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		-			-
	Outstanding at January 3, 2015		200,000		$	0.63			8.08	$	54,000

	Exercisable at January 3, 2015		95,833		$	0.63			8.08	$	25,875
Restricted stock awards granted to employees					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 28, 2013		500,000		$	0.69

	Granted		1,090,000			1.41
	Vested		-			-
	Forfeited		-			-
	Unvested shares at January 3, 2015		1,590,000		$	1.18

	Expected to Vest as of January 3, 2015		1,590,000		$	1.18

NonEmployee_ShareBased_Compens1

Non-Employee Share-Based Compensation (Tables)	12 Months Ended
Non-Employee Share-Based Compensation (Tables)	Jan. 03, 2015
Non-employee Share-based Compensation Tables
Non-Employee stock options					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 28, 2013		847,300		$	1.44		5.74

	Options Granted		90,000			1.24		10
	Options Classification from Employe to Non-Employee		113,151			0.76
	Options Exercised		-			-
	Options Forfeited		-			-
	Outstanding at January 3, 2015		1,050,451		$	1.35		5.46	$	37,550

	Exercisable at January 3, 2015		971,701		$	1.36		5.12	$	37,550
Warrant award assumptions		27-Oct-14
	Volatility		66.9	%
	Expected dividends		0	%
	Contractual term	2.0 years
	Risk-free rate		0.41	%
Restricted stock award activity					Weighted Average
		Shares			Fair Value
	Unvested shares at December 28, 2013		-		$	-

	Granted		96,000			1.3
	Vested		(20,000	)		1.17
	Forfeited		-			-
	Unvested shares expected to vest at January 3, 2015		76,000		$	0.9

Warrants_Tables

Warrants (Tables)	12 Months Ended
Warrants (Tables)	Jan. 03, 2015
Warrants Tables
Warrants					Weighted Average
							Remaining			Aggregate
		Number of			Exercise		Contractual			Intrinsic
		Shares			Price		Term			Value
	Outstanding at December 29, 2012		10,056,914		$	0.72		0.44

	Warrants Issued
	Warrants Exercised		(8,338,564	)		0.25
	Warrants Expired		(1,718,350	)		3
	Outstanding at December 28, 2013		-			-

	Warrants Issued		469,020			1.07		4.68
	Warrants Exercised		-			-
	Warrants Expired		-			-
	Outstanding and exercisable at January 3, 2015		469,020		$	1.07		4.43	$	-

Commitments_and_Contingencis_T

Commitments and Contingencis (Tables)	12 Months Ended
Commitments and Contingencis (Tables)	Jan. 03, 2015
Commitments Tables
Minimum future rental payments	Fiscal years ending:
	2015	$	544,000
	2016		319,000
	2017		225,000
	2018		233,000
	2019		181,000
		$	1,502,000
Minimum royalties including license maintenance fees	Fiscal years ending:
	2015	$	272,000
	2016		283,000
	2017		320,000
	2018		338,000
	2019		339,000
		$	1,552,000

Business_Segmentation_and_Geog1

Business Segmentation and Geographical Distribution (Tables)	12 Months Ended
	Jan. 03, 2015
Business Segmentation And Geographical Distribution Tables
Business Segmentation and Geographical Distribution
	Year ended	Core Standards and		Ingredients		Regulatory		Other			Total
	3-Jan-15	Contract Services		segment		Consulting segment
		segment

	Net sales	$	7,487,189	$	6,857,177	$	968,813	$	-		$	15,313,179
	Cost of sales		5,141,667		4,257,347		588,500		-			9,987,514

	Gross profit		2,345,522		2,599,830		380,313		-			5,325,665

	Operating expenses:
	Sales and marketing		975,800		1,081,209		79,575		-			2,136,584
	General and administrative		-		-		-		8,374,601			8,374,601
	Loss from investment in affiliate		-		-		-		45,829			45,829
	Operating expenses		975,800		1,081,209		79,575		8,420,430			10,557,014

	Operating income (loss)	$	1,369,722	$	1,518,621	$	300,738	$	(8,420,430	)	$	(5,231,349	)

	Year ended	Core Standards and		Ingredients		Scientific and		Other			Total
	28-Dec-13	Contract		segment		Regulatory
		Services				Consulting segment
		segment

	Net sales	$	6,643,832	$	2,430,699	$	1,146,718	$	(60,285	)	$	10,160,964
	Cost of sales		4,893,649		1,501,187		632,037		955			7,027,828

	Gross profit (loss)		1,750,183		929,512		514,681		(61,240	)		3,133,136

	Operating expenses:
	Sales and marketing		1,459,620		752,121		14,705		131,159			2,357,605
	General and administrative		-		-		-		5,117,016			5,117,016
	Loss from investment in affiliate		-		-		-		44,961			44,961
	Operating expenses		1,459,620		752,121		14,705		5,293,136			7,519,582

	Operating income (loss)	$	290,563	$	177,391	$	499,976	$	(5,354,376	)	$	(4,386,446	)


	At January 3, 2015	Core Standards and		IngrediEnts		Scientific and		Other			Total
		Contract Services		segment		Regulatory
		segment				Consulting
						segment

	Total assets	$	3,220,518	$	3,757,073	$	105,711	$	4,524,906		$	11,608,208



	At December 28, 2013	Core Standards and		Ingredients		Scientific and		Other			Total
		Contract		segment		Regulatory
		Services				Consulting segment
		segment

	Total assets	$	2,952,270	$	1,083,856	$	139,765	$	4,811,001		$	8,986,892

Nature_of_Business_and_Liquidi1

Nature of Business and Liquidity (Details Narrative) (USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013	Dec. 29, 2012
Liquidity
Operating loss	($5,231,349)	($4,386,446)
Net loss	-5,388,185	-4,419,525
Cash and cash equivalents	3,964,750	2,261,336	520,000
Term loan maximum borrowing capacity	5,000,000
Proceeds from loan	2,500,000
Available for borrowing	$2,500,000
Term loan interest rate	9.35%

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	12 Months Ended	22 Months Ended	56 Months Ended
Significant Accounting Policies (Details)	Dec. 28, 2013	Apr. 19, 2010	Jan. 02, 2015
Accounting Policies [Abstract]
Volatility	75.00%	402.00%	77.00%
Average Daily Trading Volume		11,455	155,111

Significant_Accounting_Policie4

Significant Accounting Policies (Details 1)	12 Months Ended	22 Months Ended	56 Months Ended
Significant Accounting Policies (Details 1)	Dec. 28, 2013	Apr. 19, 2010	Jan. 02, 2015
Volatility	75.00%	402.00%	77.00%
ChromaDex [Member]
Volatility	243.00%
Benchmark 1 [Member]
Volatility	35.00%
Benchmark 2 [Member]
Volatility	30.00%

Significant_Accounting_Policie5

Significant Accounting Policies (Details 2) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Inventories
Reference standards	$1,760,305	$1,769,160
Bulk ingredients	2,298,036	694,965
Inventory-gross	4,058,341	2,464,125
Less valuation allowance	324,000	260,000
Inventory-net	$3,734,341	$2,204,125

Significant_Accounting_Policie6

Significant Accounting Policies (Details 3)	12 Months Ended
Significant Accounting Policies (Details 3)	Jan. 03, 2015
Leaseholds and Leasehold Improvements [Member]
Useful life description	Until the end of the lease term
Computer Equipment [Member] \| Minimum [Member]
Useful life	3 years
Computer Equipment [Member] \| Maximum [Member]
Useful life	5 years
Furniture and Fixtures [Member]
Useful life	7 years
LaboratoryEquipment [Member]
Useful life	10 years

Significant_Accounting_Policie7

Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
Significant Accounting Policies (Details Narrative) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Shipping and handling fees billed	$115,000	$110,000
Cost of shipping and handling	130,000	128,000
Research and development costs	514,000	134,000
Advertising expense	$171,000	$355,000
Stock options, Volatility	75.00%	33.00%
ChangeInAccountingEstimateDescription \| Minimum [Member]
Weight on Compay's historical Volatility rate	20.00%
ChangeInAccountingEstimateDescription \| Maximum [Member]
Weight on Compay's historical Volatility rate	75.00%

Loss_Per_Share_Applicable_to_C2

Loss Per Share Applicable to Common Stockholders (Details) (USD $)	12 Months Ended
	Jan. 03, 2015		Dec. 28, 2013
Earnings per share
Net loss	($5,388,185)		($4,419,525)
Basic and diluted loss per common share	($0.05)		($0.04)
Weighted average common shares outstanding	106,459,379	[1]	99,987,443	[1]
Stock Options [Member]
Potentially dilutive securities
Diliutive securities	13,974,052	[2]	13,160,955	[2]
Warrant [Member]
Potentially dilutive securities
Diliutive securities	469,020	[2]		[2]
Convertible Debt Securities [Member]
Potentially dilutive securities
Diliutive securities	$773,395	[2]		[2]

[1]	Includes 1,623,186 and 500,000 weighted average nonvested shares of restricted stock for the year 2014 and 2013, respectively, which are participating securities that feature voting and dividend rights.
[2]	Excluded from the computation of loss per share as their impact is antidilutive.

Investment_in_Affiliate_Detail

Investment in Affiliate (Details) (USD $)	12 Months Ended		3 Months Ended	6 Months Ended
Investment in Affiliate (Details) (USD $)	Jan. 03, 2015	Dec. 28, 2013	Dec. 31, 2015	Sep. 30, 2013
Gross profit	$5,325,665	$3,133,136
Net loss	-5,388,185	-4,419,525
NeutriSci [Member]
Sales			60,575	36,451
Gross profit			33,619	13,310
Net loss			($435,208)	($813,212)

Investment_in_Affiliate_Detail1

Investment in Affiliate (Details 1) (NeutriSci [Member], USD $)	9 Months Ended	12 Months Ended
	Dec. 28, 2013	Jan. 03, 2015	Dec. 29, 2012
NeutriSci [Member]
Carrying value, equity investment, beginning balance	$2,157,804	$1,887,844	$2,157,804
Company's share of NeutriSci's loss during period	-44,961	-21,543
Proceeds from assignment of the Senior Note		-1,092,500
Proceeds from sale and transfer of the Preferred Shares		-749,515
Proceeds (loss) from investment in affiliate	-225,000	-24,286
Carrying value, equity investment, ending balance	$1,887,844		$2,157,804
Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
Ownership percentage, beginning of period	5.70%	4.90%
Ownership percentage, end of period	4.90%	0.00%

Investment_in_Affiliate_Detail2

Investment in Affiliate (Details Narrative) (USD $)	1 Months Ended	12 Months Ended	1 Months Ended
Investment in Affiliate (Details Narrative) (USD $)	Dec. 30, 2013	Dec. 28, 2013	Dec. 01, 2014	Jan. 03, 2015	Mar. 28, 2013
Senior note to an unrelated party	$1,250,000
Remaining outstanding on the Senior Note at the date of assignment	2,275,000
Legal fees	7,500
NeutriSci Preferred shares due to an unrelated party	500,000
Placement agent cash fee	150,000
NeutriSci Preferred shares due to Palladium	50,000
NeutriSci [Member]
Sale transaction value, cost recovery method		3,157,804
Cash payment for agreement		1,000,000
Secured note		2,500,000
Convertible shares		625,000
Series I preferred shares issued		669,708
Series I conversion into Class A Common Shares		2,678,832
Class A common percent of deemed shares		19.00%
Carrying value, equity investment, beginning balance		2,157,804			2,157,804
Cash payment received		225,000
Series I Unrelated Party 1 [Member]
Series I preferred shares transferred			108,676
Series I Paladium [Member]
Series I preferred shares transferred			10,868
Series I Unrelated Party 2 [Member]
Sale of preferred stock, shares			551,114
Proceeds from sale of preferred stock			749,515
Loss on sale of preferred stock			-24,286
Value of preferred stock sold			773,801

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Intangible assets
Gross Carrying Amount	$1,205,275	$909,224
Accumulated Amortization	$1,075,285	$873,635

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Jan. 03, 2015
Finite Lived Intangible Assets Future Amortization Expense
2015	$40,000
2016	40,000
2017	40,000
2018	36,000
2019	33,000
Thereafter	107,000
Intangible assets	$296,000

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	12 Months Ended
Intangible Assets (Details Narrative) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Intangible Assets Details Narrative
Amortization expense on amortizable intangible assets	$35,589	$23,532
Unamortized expense to be recognized over a weighted average period	7 years 3 months 18 days

Leasehold_Improvements_and_Equ2

Leasehold Improvements and Equipment (Details) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Leasehold improvements
Laboratory equipment	$3,151,748	$2,782,364
Leasehold improvements	495,240	491,125
Computer equipment	329,737	372,851
Furniture and fixtures	13,039	18,313
Office equipment	7,877	7,877
Construction in progress	68,141	40,126
Leasehold improvements, gross	4,065,782	3,712,656
Less accumulated depreciation	2,801,122	2,649,417
Leasehold improvements, total	$1,264,660	$1,063,239

Leasehold_Improvements_and_Equ3

Leasehold Improvements and Equipment (Details Narrative) (USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
Leasehold Improvements And Equipment Details Narrative
Depreciation expense	$222,721	$246,175
Capitalized lease obligations expense	1,073,601	695,461
Capitalized lease obligations accumulated amortization	242,887	136,358
Disposal of depreciated equipment	$56,000

Capitalized_Lease_Obligations_1

Capitalized Lease Obligations (Details) (USD $)	Mar. 18, 2015	Jan. 03, 2015
Capitalized Lease Obligations Details
2015		$191,454
2016		178,563
2017		157,713
2018		108,860
2019		33,884
Total minimum lease payments	7,000	670,474
Less amount representing interest at a rate of approximately 8.8% per year		99,181
Present value of net minimum lease payments		571,293
Less current portion		148,278
Long-term obligations under capital leases		$423,015

Capitalized_Lease_Obligations_2

Capitalized Lease Obligations (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
Capitalized Lease Obligations (Details Narrative) (USD $)	Mar. 18, 2015	Jan. 03, 2015	Dec. 28, 2013
Capitalized Lease Obligations Details Narrative
Interest expense		$47,000	$34,000
Minimum lease payment	7,000	670,474
Total lease obligation	356,000	423,015	280,342
Capital lease recorded	$304,000	$322,802	$302,017

Loan_Payable_Details

Loan Payable (Details) (USD $)	0 Months Ended
Loan Payable (Details) (USD $)	Oct. 27, 2014	Sep. 29, 2014
Debt Disclosure [Abstract]
Fair value of common stock		$1.08
Volatility	66.90%	72.40%
Expected dividends	0.00%	0.00%
Contractual term	2 years	5 years
Risk-free rate	0.41%	1.76%

Loan_Payable_Details_1

Loan Payable (Details 1) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Principal amount payable for following years ended December
2015	$223,358
2016	867,247
2017	1,035,995
2018	373,400
Total principal payments	2,500,000
Accrued end of term charge	10,486
Total loan payable	2,510,486
Less unamortized debt discount	218,654
Less current portion	223,358
Loan payable - long term	$2,068,474

Loan_Payable_Details_Narrative

Loan Payable (Details Narrative) (USD $)	12 Months Ended
Loan Payable (Details Narrative) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Term loan maximum borrowing capacity	$5,000,000
Proceeds from loan	2,500,000
Available for borrowing	2,500,000
Facility charge	50,000
Term loan interest rate Maximum	9.35%
Repayment	The Loan Agreement further provides that, subject to certain conditions, any regularly scheduled installment of principal due to Lender may be paid, in whole or in part at the option of the Company or Lender, by converting a portion of the principal of the term loan into shares of the CompanyBs common stock (the BConversion SharesB) at a conversion price of $1.293, in lieu of payment in cash. The aggregate principal amount to be paid in Conversion Shares shall not exceed $1,000,000. Of this amount 50% shall convert at the LenderBs option and 50% shall convert at the CompanyBs option.
Percent Foreign Equity Securities	35.00%
default interest rate	4.00%
Debt issuance costs	-102,866
Amortization of debt issuance costs	11,505
Unamortized debt issuance costs	91,361
End of term charge payable	93,750
Additional interest expense accrued	10,486
Recognized in additional paid in capital	246,189
Interest expense	158,849	34,330
Lender [Domain]
Warrant issued	419,020
Warrant exercise price	$1.06
Amortization of debt issuance costs	27,535
Fair value of warrant issued to lender	273,081
Recognized in additional paid in capital	246,189
Interest expense	$112,000

Income_Taxes_Details

Income Taxes (Details)	12 Months Ended
Income Taxes (Details)	Jan. 03, 2015	Dec. 28, 2013
Income Taxes Details
Income tax expense (benefit) at statutory rate	-34.00%	-34.00%
State income taxes, net of federal tax effect	-5.30%	-4.30%
Permanent differences	2.70%	2.60%
Change in tax rates	-6.10%	-3.70%
Change in valuation allowance	42.80%	39.20%
Other	-0.10%	0.20%
Income Tax Expense Benefit	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Deferred tax assets:
Net operating loss carryforward	$11,401,000	$8,953,000
Stock options and restricted stock	2,934,000	1,945,000
Investment in affiliate related to BluScience transaction		1,187,000
Inventory reserve	226,000	100,000
Allowance for doubtful accounts	15,000	3,000
Accrued expenses	125,000	100,000
Deferred revenue	4,000	64,000
Intangibles	26,000	36,000
Deferred rent	81,000	99,000
Deferred Tax Assets Gross	14,812,000	12,487,000
Less valuation allowance	14,669,000	12,361,000
Deferred Tax Assets Net	143,000	126,000
Deferred tax liabilities:
Leasehold improvements and equipment	-108,000	-100,000
Prepaid expenses	-35,000	26,000
Deferred Income Tax Liabilities	-143,000	-126,000
Deferred Tax Liabilities

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
Income Taxes (Details Narrative) (USD $)	Jan. 03, 2015
Income Taxes Details Narrative
Increase in valuation allowance	$2,308,000
Federal tax net operating loss carryforwards	28,956,000
State tax net operating loss carryforwards	$29,092,000

Employee_ShareBased_Compensati2

Employee Share-Based Compensation (Details) (Options [Member])	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
Options [Member]
Expected Volatility	74.63%	32.75%
Expected dividends	0.00%	0.00%
Expected term	5 years 9 months 3 days	6 years
Risk-free rate	1.86%	1.51%

Employee_ShareBased_Compensati3

Employee Share-Based Compensation (Details 1)	12 Months Ended	22 Months Ended	56 Months Ended
Employee Share-Based Compensation (Details 1)	Dec. 28, 2013	Apr. 19, 2010	Jan. 02, 2015
Employee Share-based Compensation Details 1
Volatility	75.00%	402.00%	77.00%
Average Daily Trading Volume		11,455	155,111

Employee_ShareBased_Compensati4

Employee Share-Based Compensation (Details 2) (ServicePeriodBasedStockOptions [Member], USD $)	12 Months Ended
	Jan. 03, 2015
ServicePeriodBasedStockOptions [Member]
Number of Shares
Outstanding at Beginning of Period	12,113,655
Options Granted	2,233,987
Option classification from Employee to Non-Employee	-113,151
Options Exercised	-534,715
Options Expired	-253,900
Options Forfeited	-722,275
Outstanding at End of Period	12,723,601
Exercisable at End of Period	9,362,374
Weighted Average Exercise Price
Outstanding at Beginning of Period	$1.06
Options Granted	$1.39
Options Exercised	$0.76
Options Expired	$0.87
Options Forfeited	$1
Outstanding at End of Period	$1.13
Exercisable at End of Period	$1.13
Weighted Average Remaining Contractual Term
Outstanding at Beginning of Period	7 years 5 months 4 days
Options granted	10 years
Outstanding at End of Period	7 years
Exercisable at End of Period	6 years 4 months 24 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value outstanding	$581,050
Aggregate Intrinsic Value exercisable	$455,570

Employee_ShareBased_Compensati5

Employee Share-Based Compensation (Details 3) (Performance Based Stock Options [Member], USD $)	12 Months Ended
	Jan. 03, 2015
Performance Based Stock Options [Member]
Summary of performance based stock option activity- Shares
Outstanding at Beginning of Period	200,000
Options Granted
Options Exercised
Options Expired
Options Forfeited
Outstanding at End of Period	200,000
Exercisable at End of Period	95,833
Weighted Average Exercise Price
Outstanding at Beginning of Period	$0.63
Options Granted
Options Exercised
Options Expired
Options Forfeited
Outstanding at End of Period	$0.63
Exercisable at End of Period	$0.63
Weighted Average Remaining Contractual Term
Outstanding at Beginning of Period	9 years 29 days
Outstanding at End of Period	8 years 29 days
Exercisable at End of Period	8 years 29 days
Aggregate Intrinsic Value
Outstanding at End of Period	$54,000
Exercisable at End of Period	$25,875

Employee_ShareBased_Compensati6

Employee Share-Based Compensation (Details 4) (Restricted Stock [Member], USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
Summary of activity of restricted stock awards granted to employees- Shares
Unvested shares at Beginning of Period
Unvested shares at End of Period	76,000
Expected to Vest as of End of Period	76,000
Weighted Average Award-Date Fair Value
Unvested shares at Beginning of Period
Unvested shares at End of Period	$0.90
Expected to Vest as of End of Period	$0.90
Employee Stock Option [Member]
Summary of activity of restricted stock awards granted to employees- Shares
Unvested shares at Beginning of Period	500,000
Granted	1,090,000
Vested
Forfeited
Unvested shares at End of Period	1,590,000
Expected to Vest as of End of Period	1,590,000
Weighted Average Award-Date Fair Value
Unvested shares at Beginning of Period	$0.69
Granted	$1.41
Vested
Forfeited
Unvested shares at End of Period	$1.18
Expected to Vest as of End of Period	$1.18

Employee_ShareBased_Compensati7

Employee Share-Based Compensation (Details Narrative) (USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
Employee Share-Based Compensation
Closing stock price	$0.90
Restricted stock issued	1,090,000
Restricted stock issued, value	$1,536,900
General and Administrative Expense [Member]
Employee Share-Based Compensation
Recognized share based compensation expense (income)	2,747,000	958,000
Options [Member]
Employee Share-Based Compensation
Expiration dates for stock options not exceeds	10 years
Authorized stock options	20.00%
Remaining amount available for issuance	4,738,496
Vesting period	4 years
Unrecognized compensation expense	1,768,000
Cost is expected to be recognized over a weighted average period	2 years 2 months 12 days
Realized tax benefit from stock options	0	0
ServicePeriodBasedStockOptions [Member]
Employee Share-Based Compensation
Closing stock price	$0.90
Aggregate intrinsic value of options exercised	$156,000	$7,000
Weighted average fair value of options granted	$0.90	$0.29
Performance Based Stock Options [Member]
Employee Share-Based Compensation
Closing stock price	$0.90

NonEmployee_ShareBased_Compens2

Non-Employee Share-Based Compensation (Details) (USD $)	12 Months Ended
Non-Employee Share-Based Compensation (Details) (USD $)	Jan. 03, 2015
Non-Employee Share-Based Compensation- Options
Outstanding at Beginning of Period	847,300
Options Granted	90,000
Options Classification from Employee to Non-Employee	113,151
Options Exercised
Options Forfeited
Outstanding at End of Period	1,050,451
Exercisable at End of Period	971,701
Weighted Average Exercise Price
Outstanding at Beginning of Period	$1.44
Options Granted	$1.24
Options Classification from Employee to Non-Employee	$0.76
Options Exercised
Options Forfeited
Outstanding at End of Period	$1.35
Exercisable at End of Period	$1.36
Weighted Average Remaining Contractual Term
Outstanding at beginning of period	5 years 8 months 26 days
Options granted	10 years
Outstanding at End of Period	5 years 5 months 15 days
Exercisable at End of Period	5 years 1 month 13 days
Aggregate Intrinsic Value
Outstanding at End of Period	$37,550
Exercisable at End of Period	$37,550

NonEmployee_ShareBased_Compens3

Non-Employee Share-Based Compensation (Details 1)	0 Months Ended
Non-Employee Share-Based Compensation (Details 1)	Oct. 27, 2014	Sep. 29, 2014
Non-Employee Warrant Award
Volatility	66.90%	72.40%
Expected dividends	0.00%	0.00%
Expected term	2 years	5 years
Risk-free rate	0.41%	1.76%

NonEmployee_ShareBased_Compens4

Non-Employee Share-Based Compensation (Details 2) (Restricted Stock [Member], USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
Summary of activity of restricted stock awards granted to Non-employees- Shares
Unvested shares at Beginning of Period
Unvested shares at End of Period	76,000
Expected to Vest as of End of Period	76,000
Weighted Average Award-Date Fair Value for Non-Employee Restricted Stock
Unvested shares at Beginning of Period
Unvested shares at End of Period	$0.90
Expected to Vest as of End of Period	$0.90
Nonemployees [Member]
Summary of activity of restricted stock awards granted to Non-employees- Shares
Granted	96,000
Vested	-20,000
Forfeited
Weighted Average Award-Date Fair Value for Non-Employee Restricted Stock
Granted	$1.30
Vested	$1.17
Forfeited

NonEmployee_ShareBased_Compens5

Non-Employee Share-Based Compensation (Details Narrative) (USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013	Nov. 03, 2015
Closing stock price	$0.90
Shares awarded during the period		$2,980,000
Fair value, stock award	2,861,293	1,334,530
Restricted Stock [Member] \| Nonemployees [Member]
Unrecognized expense	68,000
Cost is expected to be recognized over a weighted average period	3 years 2 months 12 days
Fair value, stock award	24,000
NonEmployee Share Based Compensation [Member] \| Stock Options [Member]
Aggregate intrinsic value, options exercised		35,000
Unrecognized expense	44,000
Cost is expected to be recognized over a weighted average period	1 year 8 months 12 days
NonEmployee Share Based Compensation [Member] \| StockAward [Member]
Unrecognized expense			11,000
Cost is expected to be recognized over a weighted average period	1 month
Shares awarded during the period		600,000
Compensation expense	129,000	325,000
NonEmployee Share Based Compensation [Member] \| StockAward [Member] \| StockAward 1 [Member]
Cost is expected to be recognized over a weighted average period	7 months
Shares awarded during the period	65,000
Fair value, stock award	83,850
NonEmployee Shared Based Compensation [Member] \| WarrantAward [Member]
Unrecognized expense	10,000
Cost is expected to be recognized over a weighted average period	4 months
Shares awarded during the period	50,000
Exercise price	$1.10	$0.75
Warrant term	2 years
Compensation expense	6,000	4,000
Intrinsic value, warrant exercised		$90,507

Stock_Issuance_Details_Narrati

Stock Issuance (Details Narrative) (USD $)	12 Months Ended
Stock Issuance (Details Narrative) (USD $)	Dec. 28, 2013	Jan. 03, 2015	Jun. 18, 2014	Jun. 11, 2014
Stock Issuance
Common stock issued	104,524,738	105,271,058
Sale of common stock	3,500,000
Proceeds from sale of common stock	$2,980,000
Placement agent fee	20,000
Vendor [Member]
Stock Issuance
Common stock issued			82,000	44,605
Common stock issued, value			76,306	52,188
Monthly Retainer fees			$3,000

Warrants_Details

Warrants (Details) (USD $)	12 Months Ended
Warrants (Details) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Warrants Details
Warrants outstanding at beginning of period		10,056,914
Warrants Issued	469,020
Warrants Exercised		-8,338,564
Warrants Expired		-1,718,350
Warrants outstanding at end of period	469,020
Warrants exercisable at end of period
Weighted Average Exercise Price
Outstanding at beginning of period		$0.72
Warrants issued	$1.07
Warrants exercised		$0.25
Warrant expired		$3
Outstanding at end of period	$1.07
Exercisable at end of period	$1.07
Remaining Contractual Term, beginning of period		5 months 8 days
Weighted average contractual term, warrants issued	4 years 8 months 4 days
Remaining Contractual Term, end of period	4 years 5 months 4 days

Warrants_Details_Narrative

Warrants (Details Narrative) (USD $)	12 Months Ended
Warrants (Details Narrative) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Closing stock price	$0.90
Warrants issued/awarded	469,020
Hercules [Member]
Warrants issued/awarded	419,020
Exercise price of warrant	$1.06
Nonemployee [Member]
Warrants issued/awarded	50,000
Exercise price of warrant	$1.10

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Jan. 03, 2015
Minimum Future Rental Payments
2015	$544,000
2016	319,000
2017	225,000
2018	233,000
2019	181,000
Minimum future rental payments	$1,502,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details 1) (USD $)	Jan. 03, 2015
Minimum Future Royalties
2015	$272,000
2016	283,000
2017	320,000
2018	339,000
2019	339,000
Minimum royalties including license maintenance fees	$1,552,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Narrative) (USD $)	12 Months Ended
Commitments and Contingencies (Details Narrative) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Lease
Rent expense	$537,000	$519,000
Royalty
Royalty expense including license maintenance fees	323,000	111,000
Jaksch [Member]
Severance payments to executive officers
Employment agreement term	3 years
Salary	275,000
Maximum Bonus target	50.00%
Varvaro [Member]
Severance payments to executive officers
Employment agreement term	3 years
Salary	225,000
Maximum Bonus target	40.00%
Rhonemus [Member]
Severance payments to executive officers
Salary	180,000
Maximum Bonus target	30.00%
Minimum [Member]
Lease
Monthly lease payment	1,320
Royalty
Minimum yearly royalty payments	5,000
Royalty payable on sales	2.00%
Maximum [Member]
Lease
Monthly lease payment	22,788
Royalty
Minimum yearly royalty payments	50,000
Royalty maximum	$150,000
Royalty payable on sales	5.00%

Business_Segmentation_and_Geog2

Business Segmentation and Geographical Distribution (Details) (USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
Net sales	$15,313,179	$10,160,964
Cost of sales	9,987,514	7,027,828
Gross profit (loss)	5,325,665	3,133,136
Sales and marketing	2,136,584	2,357,605
General and administrative	8,374,601	5,117,016
Loss from investment in affiliate	45,829	44,961
Operating expenses	10,557,014	7,519,582
Operating income (loss)	-5,231,349	-4,386,446
CoreStandardsContractServices [Member]
Net sales	7,487,189	6,643,832
Cost of sales	5,141,667	4,893,649
Gross profit (loss)	2,345,522	1,750,183
Sales and marketing	975,800	1,459,620
General and administrative
Loss from investment in affiliate
Operating expenses	975,800	1,459,620
Operating income (loss)	1,369,722	290,563
Ingredients Segment [Member]
Net sales	6,857,177	2,430,699
Cost of sales	4,257,347	1,501,187
Gross profit (loss)	2,599,830	929,512
Sales and marketing	1,081,209	752,121
General and administrative
Loss from investment in affiliate
Operating expenses	1,081,209	752,121
Operating income (loss)	1,518,621	177,391
Regulatory Consulting [Member]
Net sales	968,813	1,146,718
Cost of sales	588,500	632,037
Gross profit (loss)	380,313	514,681
Sales and marketing	79,575	14,705
General and administrative
Loss from investment in affiliate
Operating expenses	79,575	14,705
Operating income (loss)	300,738	499,976
Other Segment [Member]
Net sales		-60,285
Cost of sales		955
Gross profit (loss)		-61,240
Sales and marketing		131,159
General and administrative	8,374,601	5,117,016
Loss from investment in affiliate	45,829	44,961
Operating expenses	8,420,430	5,293,136
Operating income (loss)	($8,420,430)	($5,354,376)

Business_Segmentation_and_Geog3

Business Segmentation and Geographical Distribution (Details1) (USD $)	Jan. 03, 2015	Dec. 28, 2013
Total assets	$11,608,208	$8,986,892
CoreStandardsContractServices [Member]
Total assets	3,220,518	2,952,270
Ingredients Segment [Member]
Total assets	3,757,073	1,083,856
Regulatory Consulting [Member]
Total assets	105,711	139,765
Other Segment [Member]
Total assets	$4,524,906	$4,811,001

Business_Segmentation_and_Geog4

Business Segmentation and Geographical Distribution (Details Narrative) (USD $)	12 Months Ended
	Jan. 03, 2015	Dec. 28, 2013
CoreStandardsContractServices [Member]
Revenue from international sources	$1,756,000	$1,488,000
Ingredients Segment [Member]
Revenue from international sources	35,000	22,000
Scientific Regulatory [Member]
Revenue from international sources	$104,000	$450,000

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	3 Months Ended
Subsequent Events (Details Narrative) (USD $)	Mar. 18, 2015
Subsequent events
Common stock issued for services	350,000
Brauser [Member]
Subsequent events
Stock options vested	26,667
Stock options exercise price	1.25
Shares of restricted stock vested	250,000
Honig [Member]
Subsequent events
Stock options vested	26,667
Stock options exercise price	1.25
Shares of restricted stock vested	250,000